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ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia and accounts for
60-80 % of all dementia cases. In the United States, AD is ranked as the 6th leading cause
of death and it is the only one among the top 10 that cannot be prevented, treated or even
slowed. All FDA approved drugs focus on attenuating the symptoms for a limited time by
regulating neurotransmitters without any intervention with the underlying disease process.
A major player in the initiation and development of this debilitating disorder is the
misfolding and subsequent aggregating of amyloid-β (Aβ) peptide. This aggregation
process converts non-toxic functional Aβ peptides into a spectrum of neurotoxic Aβ
aggregated species, such as, oligomers, soluble aggregates and fibrils. These aggregated
forms are believed to be the source of inflammation and oxidative stress that cause neuron
death and the loss of synaptic functions. Therefore, small molecules that could intervene
with the aggregation of Aβ peptides may present an effective AD therapeutic prevention
and treatment.
The work presented here examined the intervening effects of eight stilbenes, such
as resveratrol and piceatannol, on multiple mechanistic steps of Aβ aggregation. Results
identified trans-piceatannol and cis-piceatannol as the most potent compounds that could
affect distinct aggregation pathways, specifically, modifying the conformation of Aβ
aggregates, as well as, reducing soluble aggregate growth rate. The pronounced change in
Aβ aggregate conformation might be related to a change in cytotoxicity. Their superior
effects could be attributed to the presence of catechol moiety. The change in Aβ aggregate
iii

conformation induced by trans-piceatannol substantially reduced the Aβ aggregates
binding to lipid bilayers, which plays a vital role in the induction of neurotoxicity. Other
stilbenes, including resveratrol, also altered the morphology of Aβ aggregates but they
exhibited only moderate interfering effects on Aβ aggregation pathways. Together, this
study provides insight into the effective interventions of piceatannol on Aβ aggregation
and proposes this natural compound as a novel promising small molecule for the prevention
and treatment of AD.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
1.1 Alzheimer’s Disease
Alzheimer’s disease (AD), accounting for 60-80 % of all dementia cases, has
gained worldwide attention. In 2012, the month of September was designated as World
Alzheimer’s Month, and September 21st was named World Alzheimer’s Day for the
purpose of raising awareness and spreading knowledge of AD. AD is a progressive, chronic
neurodegenerative disorder, which mainly affects people older than 65. Thus, age is a
major risk factor for AD. However, the cause of AD is complex and believed to be a
combination of multiple risk factors, such as, diet, family history, apolipoprotein E
(APOE)-ε4 gene inheritance, social and cognitive engagement, and traumatic brain injury
[1]. The mild AD symptoms include short-term memory loss, depression, mood swings
and difficulty in problems solving. Severe AD patients show symptoms such as temporal
and spatial confusion, visual problems and even loss of the ability to walk or swallow.
Eventually, AD causes death. Patients who are older than 65 usually only live for another
4 to 8 years after their diagnosis [2].
In the United States, this disease is ranked as the 6th leading cause of death and it is
the only one among the top 10 that cannot be prevented, treated or even slowed [3]. All
five FDA approved drugs focus on attenuating the symptoms for a limited time by
regulating neurotransmitters without any intervention with the underlying disease process.
From 2000 to 2013, as deaths attributed to other major diseases decreased significantly
1

(heart disease 14%, stroke 23%, HIV 52%), deaths caused by AD have increased by 71%
[2]. It has recently been labeled the “twenty-first century plague” [4] with 5.4 million
Americans suffering from AD in 2016 and 40 million worldwide. It is predicted the number
of patients will increase to 13.8 million in the US and 150 million globally by 2050 if no
more effective treatment can be developed to intervene [2]. With such a high mortality,
prevalence and incidence, AD is becoming an increasingly heavy burden for society and it
is urgent to pursue effective new therapeutic methods which slow the pathological progress
or even stop the development of the disease.
1.2 Amyloid-b Protein Aggregation
Physiologically, AD is characterized by the extracellular deposition of neuritic
plaques, which are constituted of amyloid-β (Aβ) peptide aggregated fibrils and the
intracellular accumulation of neurofibrillary tangles (NFTs), which are composed of
hyperphosphorylated tau proteins in human brain tissues. While plaques and tangles
coexist in AD brains, plaques are specific for AD since NFTs can occur by themselves and
cause other types of dementias, such as frontotemporal dementia and chronic traumatic
encephalopathy. Some studies suggested that NFTs formation is a downstream event of Aβ
aggregation [5], and NFTs have been observed to disperse after the removal of Aβ plaques
[6]. These observations provide support for the amyloid cascade hypothesis (postulated by
Hardy and colleagues in 1992 [7]), which established a causal link between Aβ aggregation
and the disease. It remains as the leading hypothesis for the pathology of AD. Over the past
twenty-five years, a few slight modifications were made, but the concept of this hypothesis
is commonly accepted and supported by experimental data [8].
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Aβ peptide mainly exists in two isoforms: Aβ40, 40 amino acids in length, is the
most common isoform (90%); and Aβ42, with an additional two hydrophobic amino acids
at the C-terminus based on Aβ40, has higher aggregation propensity due to its greater
hydrophobicity. Aβ peptides are derived from the proteolytic cleavages of a
transmembrane glycoprotein, amyloid precursor protein (APP), by enzyme β-secretase at
the N-terminus of APP and enzyme γ-secretase at the C-terminus of APP. The location of
C-terminal γ-secretase cutting sites determines the type of Aβ peptide (Aβ40 or Aβ42). Aβ
peptide is present ubiquitously and formed during normal cellular metabolism [9]. It is nontoxic and some studies even suggest that it contributes to memory improvement at
physiological, low picomolar concentrations [10]. Aβ peptide levels are normally regulated
at a balance between production and clearance. Perturbations to this balance, such as Aβ
overexpression and the failure of amyloid degrading enzymes, lead to the accumulation of
excess Aβ peptide to initiate a sequence of self-aggregation that causes deleterious events
and disease.
To understand the Aβ aggregation process, we can describe it as a phenomenon of
searching for minimum on a free energy surface [11]. Aβ peptides, under normal
physiological conditions, exist in an intrinsically disordered state which is referred to as
the “native unfolded state”. This state is stable under physiological conditions because it
reflects a local free energy minimum. The transition from native forms to aggregated forms
requires Aβ peptides to overcome a high kinetic barrier. From the perspective of biological
evolution, this energy barrier might be the result of the development of complex molecular
machineries aimed at preventing the formation of toxic aggregates [12]. However, the
accumulated effects of AD risk factors, such as aging, could trigger the transformation
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from physiological conditions to misfolding conditions. Under these conditions, Aβ
peptides may overcome the energy barrier and enter an aggregation-prone state, which has
an even lower free energy than the native state. After entering this state, Aβ peptide
intermolecular interactions are favored over intramolecular interactions and their
hydrophobic cores become exposed to the solvent. These changes cause Aβ peptides to be
loosely packed and have a higher chance to nucleate into oligomeric assemblies, which
initiates a chain reaction of self-aggregation by forming nuclei and recruiting other Aβ
peptides to form larger size aggregates, such as oligomers, soluble aggregates and mature
fibrils. Aβ fibrils, with a rope-like structure, are usually straight, unbranched, 0.1-10 µm
long and 10 nm wide. They have a cross-b structure that stabilizes fibrils since it allows
the formation of a continuous array of hydrogen bonds between side chains [13]. This
secondary b structure, present in various aggregated species, is believed to lead to the
overwhelming impairment of the cell defense mechanisms and cause cell death by
apoptosis or necrosis [12].
1.3 Aβ Aggregation Mechanistic Steps
Aβ aggregation occurs via a nucleation-dependent, multi-step pathway which can
be characterized as three phases: lag phase, growth phase, and plateau phase. Lag phase is
the time period in which individual Aβ peptides (monomers) form small oligomers to serve
as aggregation nuclei. It is considered the rate limiting step since the free energy barrier
needs to be crossed for the nucleation. Lag phase cannot be readily detected in the bulk
assay because the aggregates concentration is low and these aggregates lack the β-sheet
structure which is commonly used as an indicator for aggregation extent. Once nuclei
concentration reaches a critical value, aggregation enters into growth phase. In this phase,
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Aβ aggregates rapidly grow in size by two parallel mechanisms simultaneously: elongation
via monomer addition, which increases the length of aggregates, and association via
aggregate lateral interaction, which increases the thickness of aggregates [14]. These Aβ
soluble aggregates also undergo a conformational change in which β-sheet structure is
substantially developed, and thus aggregation assays identify growth phase as a significant
signal increase. Eventually, the stable, insoluble Aβ fibrils are formed and various Aβ
species coexist in equilibrium, and this is the plateau phase. In aggregation assays, it is
represented by a constant, stable signal extending from the end of growth phase. Figure 1.1
shows the mechanistic steps of Aβ aggregation.
1.4 Aβ Aggregation and Lipid Membranes
The neurotoxicity mechanism of Aβ aggregates is complex, and there are a variety
of hypotheses that have been proposed, such as, the inflammatory effect of Aβ aggregates
on the cell membrane [15], oxidative stress [16], effect of metals [17], specific and
nonspecific interactions with cellular and lipid membranes [18,19]. Thus, the interaction
of Aβ aggregates with lipid membranes may play a vital role in the induction of
neurotoxicity. The possible changes in the membrane induced by Aβ aggregates include
thinning of the membrane, alterations in fluidity and permeability which results in lipid
oxidation and free radical production, and formation of ion channels which leads to a
dramatic increase in intracellular calcium ions [20].
With the tremendous amount of Aβ research, from both experimental and
computational perspectives, progress has been made to reveal the molecular mechanisms
that may drive Aβ to interact with the cell membrane and cause toxic effects. These
mechanisms can be divided into three types. 1) Aβ aggregates bind and deposit on the
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surface of lipid membrane without penetrating and destroy membrane structure or integrity
[15]. 2) Aβ aggregates penetrate into membranes, causing defects within the membrane
which results in functional disorders [12]. 3) Aβ aggregates induce formation of ion
channels on the membranes, which destabilizes cellular ionic homeostasis [18]. There is
abundant evidence for each of these mechanism types. It is proposed that the exact type of
damage caused by Aβ aggregates is highly dependent on both the properties of the
membranes and the attributes of Aβ aggregates. Therefore, Aβ aggregates modified by
compounds could interact with lipid membranes in a novel way, possibly from pathogenic
interaction to non-pathogenic interaction.
1.5 Stilbenes as Potential Therapeutic Agents for AD
Polyphenols are a huge family of naturally occurring and synthetic compounds that
contain hydroxylated aromatic rings. Polyphenols can be found in abundance in everyday
foods, such as gallic acid in tea, ferulic acid in cereal grains, flavonols in various fruits and
resveratrol in grapes. They have been extensively studied recently for their multiple
beneficial effects to human health and have been investigated as potential therapeutic
agents for various diseases, such as cancer, high blood pressure, heart disease and diabetes,
mainly based on their antioxidant and anti-inflammatory properties [21]. Besides,
polyphenols also have properties of interacting with peptides and proteins [22]. Since AD
is a disease caused by Aβ protein misfolding, the interactions between polyphenols and Aβ
protein might play an important role in the intervention of disease progression, and it is the
basis on which this research is developed.
Polyphenols can be categorized into subgroups based on their structures. This
research focuses on one subgroup – stilbene. Stilbene has the common structure of a central
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ethene double bond with each carbon atom of the double bond substituted with phenyl
rings, and compounds within the group differ from each other by phenyl ring R groups.
Stilbenes studied in this research are shown in Figure 1.2. Resveratrol is the most common
natural stilbene found in over 70 plants. It is most abundant in grape skins and seeds, which
are used to make wine, and the concentration of resveratrol in red wine is much higher than
that in white wine because the grape skins are present a longer time in the fermentation
process of red wine [23]. The high content of resveratrol in red wine presents resveratrol
as a possible explanation for the “French Paradox” – in spite of having a diet rich in
saturated fats, French people who consumed 2-4 glasses of red wine per day have a low
incidence of cardiovascular diseases. Moreover, epidemiological evidence suggests that
moderate consumption of red wine is associated with a reduced risk of AD [24]. The
scientific community has suggested this association could be a result of various resveratrol
and derivatives’ neuroprotective properties, such as, reducing oxidative stress [25],
inhibiting neuroinflammation [26], promoting neurogenesis and microvessel formation
[27], as well as promoting the clearance of Aβ peptide [28]. Besides resveratrol, other
stilbenes also exhibit beneficial effects for human health, for example, piceatannol has
antidiabetic, neuroprotective and cardioprotective effects [29]; oxyresveratrol has antiinflammatory, anti-herpes virus properties [30,31]; rhapontigenin is reported to have
antihyperlipidemic effects [32]; and tetramethoxystilbene has shown effects on the
treatment of breast cancer [33]. Even though there are extensive studies exploring the
therapeutic potential for stilbenes and many of the studies are targeting neurodegenerative
diseases, such as AD, few studies have explicitly investigated the interactions between
stilbenes and various steps of Aβ protein aggregation. One study [34] examined the
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inhibitory effects of stilbenes on Aβ fibril formation, but this study lacks the insights of
inspecting stilbenes intervention with other Aβ species, such as oligomers and soluble
aggregates. Also, the technique applied to monitor Aβ aggregation under the effects of
stilbenes has limitations [35]. Thus, this research is aimed at filling this void by evaluating
stilbenes interfering effects with a variety of Aβ aggregated species which might play an
important role in the prevention and treatment of AD.
1.6 Specific Aims
This study evaluated stilbenes capabilities to alter the overall and individual
mechanistic steps of Aβ aggregation related with AD. Since native Aβ aggregates are toxic
and cause the initiation and development of AD, alterations of these Aβ aggregates away
from their native forms might have a beneficial effect on slowing the disease progression.
Stilbenes intervention with Aβ aggregation are described in Chapter 3 (resveratrol and
derivatives) and Chapter 4 (piceatannol and derivatives). In Chapter 5, native Aβ
aggregates interaction with lipid membranes, the location where the neurotoxic cascade of
Aβ may be initiated, was studied and compared with that of the piceatannol modified Aβ
aggregates.
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Figure 1.1 Mechanistic steps of Ab aggregation. Ab aggregation occurs vis three phases: lag phase, where oligomers
are formed; growth phase, where soluble aggregates grow through association and elongation; and plateau phase, where
fibrils are formed and various Ab species coexist in equilibrium.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Aβ40 and Aβ42 used for this study were purchased either from AnaSpec (San Jose,
CA) or from Peptide 2.0 (Chantilly, VA). Thioflavin T (ThT), sodium chloride (NaCl),
sodium hydroxide (NaOH), phosphate buffered saline (PBS), 1,1,1,3,3,3-Hexafluoro-2propanol (HFIP), chloroform, bovine serum albumin (BSA), 3,3’-dithioproponic acid
(DDP),

N-hydroxy

succinimide

(NHS),

N-(2-dimethylamino-propyl)-N’-

ethylcarbodiimide hydrochloride (EDC) and HEPES were purchased from Sigma-Aldrich
(St. Louis, MO). Rabbit-anti-amyloid fibrils antibody (LOC) was purchased from EMD
Millipore (Billerica, MA). Dimethyl sulfoxide (DMSO) and Tween-20 were purchased
from VWR (Radnor, PA). SuperSignal West Pico enhanced chemiluminescent substrate
(ECL) was purchased from Thermo Fisher Scientific (Waltham, MA). Mouse-anti-Aβ16
antibody (6E10) was purchased from Covance (Princeton, NJ). Horseradish peroxidase
(HRP) conjugated goat-anti-rabbit IgG, Precision Plus WesternC standard, Precision
Protein Strep Tactin-HRP conjugate, and Laemmli buffer were purchased from Bio-Rad
(Hercules, CA). HRP-conjugated sheep-anti-mouse IgG was purchased from GE
Healthcare (Piscataway, NJ). 8-Anilino-1-naphthalenesulphonic acid (ANS) was
purchased from Research Organics (Cleveland, OH). Uranyl acetate was purchased from
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Electron Microscopy Science (Hatfield, PA). Triethylene glycol monoamine was
purchased from Molecular Biosciences (Boulder, CO).
2.2 Preparation of Aβ40 Monomer
Lyophilized Aβ40 was stored at -20 ºC, desiccated in 1 mg aliquots. Before use,
Aβ40 was dissolved in 50 mM NaOH to yield an Aβ40 final concentration of 2 mg/mL and
incubated for 10 min. Aβ40 peptide has a theoretical isoelectric point near 5.31 [36], a pH
at which Aβ40 has zero net charge and low solubility that leads Aβ40 to aggregate and
precipitate. The use of NaOH avoids passage through this isoelectric point en route to a
neutral pH and, thus, the isoelectric precipitation of Aβ40 is eliminated. Subsequently, the
solution was injected onto a size-exclusion chromatography (SEC) Superdex 75 HR 10/300
column (GE Healthcare, Piscataway, NJ). SEC is a chromatographic method used to
separate macromolecules, such as proteins, based on their size. The column is packed with
beads of resin which form pore space for small molecules to enter, and therefore larger
molecules pass the column in a shorter route and elute earlier than smaller molecules. 40
mM Tris-HCl (pH 8.0) is used as the SEC running buffer. In order to reduce nonspecific
binding between Aβ40 and the dextran matrix of the column, the column was pretreated
with 2 mg/mL BSA before the injection of Aβ40. Monomeric Aβ40 was eluted in the volume
of 12-15 mL, as shown in Figure 2.1A. The Aβ40 monomer concentrations were determined
by UV spectrophotometry based on Beer-Lambert law (Eq. 2.1).
! = $%&' (/*

Eq. 2.1

In the equation, the molar concentration of Aβ40 monomer (c) is calculated from
the UV absorbance at 276 nm wavelength (A276), the cuvette path length (d), which is fixed
at 1 cm, and the molar extinction coefficient at 276 nm (ε) with a value of 1450 M-1cm-1
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for Aβ40 monomer [14]. Purified Aβ40 monomer samples were used immediately or stored
at 4 ˚C for up to 3 days to prevent self-aggregating.
2.3 Aβ40 Monomer Aggregation
SEC-isolated Aβ40 monomer was diluted in 40 mM Tris-HCl to a concentration of
20 µM. A DMSO dissolved compound was added to each monomer solution. A sample
with the addition of DMSO alone was prepared as a control to represent the native
aggregation of Aβ40 monomer without influence of compounds. Aggregation was
promoted by the addition of 150 mM NaCl. Samples were incubated at 25 ºC with
continuous agitation on vortex (500 rpm). At specific time points, along aggregation
process, reaction mixture was taken for analysis either by dot blot or dynamic light
scattering (DLS).
2.3.1 Dot Blot Monitoring
Antibody detection is a widely used method to quantify a particular protein that is
recognizable by the antibody utilized. For Aβ aggregates, there are two classes of
antibodies: sequence specific and conformational specific. Sequence specific antibodies,
such as 6E10 and 4G8, bind to specific regions of Aβ peptide, and thus recognize all Aβ
species regardless of their secondary structures, including monomers, oligomers and larger
aggregates. Conformational specific antibodies, such as A11 and LOC, recognize Aβ
species with certain structural elements, and thus provide information for the development
of secondary structures. In the case of monitoring Aβ aggregation, LOC is a perfect
indicator since it only binds to specific β-sheet structure and has limited affinity to Aβ
monomer and oligomer that do not possess β-sheet structures.
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4 µL of reaction mixture was applied on a strip of 0.1 µm pore size nitrocellulose
membrane (Bio-Rad, Hercules, CA). The strips were blocked with blocking buffer – 5%
nonfat milk in phosphate buffered saline containing 0.1% Tween 20 (PBST) – overnight at
4 ºC. After blocking, the strips were washed 3 times for 5 min each via shaking in PBST
solution. Then, the strips were incubated with primary antibody LOC in blocking buffer
(1:5000) for 1 h with shaking at 25 ºC. Strips were then washed in PBST and subsequently
incubated with secondary antibody, HRP-conjugated goat-anti-rabbit IgG, in blocking
buffer (1:3000) for 45 min with shaking at 25 ºC. The strips were then washed again, and
chemiluminescence was enhanced with the ECL Chemiluminescence kit. Dot blot images
were acquired via a Bio-Rad ChemiDocTM XRS+ image system, and quantitative analysis
of LOC intensity was performed using Bio-Rad Image LabTM software. Results were
plotted as LOC antibody intensity versus time.
2.3.2 DLS Monitoring
DLS is a noninvasive method that has been used to determine size and shape
properties of macromolecules on a length scale of 1-1000 nm [37]. The general DLS set up
is shown in Figure 2.2A. A beam of light is focused onto a sample. An attenuator is often
used to adjust the laser power. Particles within the sample diffract the light in all directions,
including at a 90 degree angle, at which a detector measures and records real-time light
intensity. These scattered light intensities interfere with each other by destructive and
constructive additions and create a speckle pattern (Figure 2.2B). The speckle pattern
changes with time because there is a constant fluctuation in scattered light intensity caused
by the constant, random Brownian motion of particles in solution. The light intensity
fluctuation is related to the rate of Brownian motion by a property called translational
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diffusion coefficient. DLS, by obtaining the translational diffusion coefficient of particles
from changes in the speckle pattern, can calculate the hydrodynamic radius (RH, the radius
of a hypothetical hard sphere that has the same diffusivity with the particle under
examination) of the particles using Stokes-Einstein equation (Eq. 2.2), in which kB, T, h
and D are the Boltzmann constant, absolute temperature, solvent viscosity, and diffusivity
respectively.
+, =

-. /
'012

Eq. 2.2

Rather than directly measuring the intensity fluctuations arising from the Brownian
motion of particles, it is more efficient to use a digital auto correlator to compare the
similarity of light intensity between two time points and fit a correlation function for these
similarities at different time points. The rate of correlation change is informative for the
particle size: the slower the correlation reduces, the large the particles are. Various
algorithms can be used to obtain size information from the correlation function. The
equipment used in this study employs the Cumulant analysis, in which a single particle size
mode is assumed and a single exponential fit is applied to the correlation function. This
analysis calculates both the mean size of particles and the polydispersity that describes the
width of the assumed Gaussian distribution [38].
Applying DLS to monitor Aβ40 aggregation has two main concerns: Aβ40
aggregates have a complex structure and various Aβ40 species form a highly polydisperse
system. With respect to the first concern, the translational diffusion coefficient, in fact,
depends not only on the size of the particle, but also on the surface structures, and these
factors are not taken into consideration in RH calculations using the Stokes-Einstein
equation. Moreover, Aβ40 aggregates, especially insoluble fibrils, have a rod-like shape,
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and different Aβ40 species exist in distinct conformations. This highly non-spherical shape
affects the diffusion speed to an extent that rotational diffusion must also be considered;
otherwise, the RH calculated will not represent the real size. With respect to the second
concern, Cumulant analysis assumes the sample is a single particle size mode and applies
a single exponential fit to the assumed Gaussian distribution. For protein analysis, percent
polydispersity less than 20% indicates the sample is monodisperse [38]. In order to fit a
Gaussian distribution, percent polydisperse cannot be larger than 57.1%. In contrast to
SEC-isolated soluble aggregates (more in detail in Section 2.9), an Aβ40 aggregation
reaction is highly polydisperse with a size range from as small as a few nanometers to
hundreds of nanometers, which results in difficulty and inaccuracy for the software to
calculate the representative mean RH. From our previous experiments, we observed that as
aggregation progressed, the reading of RH became highly unstable and the majority of the
data acquisitions have higher than 57.1% percent polydispersity. For the above limitations,
we did not use measurements of RH as an indicator of the extent of aggregation, but
alternatively used scattered light intensity whose magnitude is indicative of the overall
solution particles’ size and complex structure development, which is representative of
aggregation extent. A graph of intensity versus time for Aβ40 monomer aggregation has all
the components of a typical aggregation, namely, lag phase, growth phase and plateau
phase. Here, however, the intensity change is a combined result of both size growth and
conformational change.
12 µL of the reaction mixture was loaded into the cuvette located in a DynaPro
MSX DLS instrument (Wyatt Technology Corporation, Santa Barbara, CA). The incident
light has a wavelength of 834 nm, and the intensity of its scattered light was detected at a
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90 degree angle. Each measurement utilized 20 acquisitions with an acquisition time of 5
s. The average of 20 readings was used as the quantified intensity for that measurement to
minimize the influence of intensity fluctuation. Results were plotted as scattered light
intensity versus time.
2.4 Preparation of Aβ40 Fibril
SEC-isolated Aβ40 monomer was diluted in 40 mM Tris-HCl with addition of NaCl
to yield a solution with final concentrations of 60 µM Aβ40 monomer and 250 mM NaCl.
The reaction mixture was agitated continuously for at least 24 h at 800 rpm and 25 ºC to
obtain stable mature fibril. Then fibril was separated from monomer and other soluble
aggregate via centrifugation (14,000 rpm, 15 min). After the supernatant was removed, the
pellet was resuspended in the same volume of 40 mM Tris-HCl with the reaction mixture
solution in which fibrils were formed. The concentration of fibril was determined using the
original monomeric Aβ40 concentration (60 µM) corrected by measuring and comparing
ThT fluorescence for samples before and after centrifugation. ThT dye is widely used as
an indicator for Aβ monomer aggregation based on its fluorescent properties. After ThT
binds to β-sheet structures in amyloid aggregates, it displays an enhanced fluorescence with
a shifted excitation maximum from 385 to 450 nm and a shifted emission maximum from
445 to 482 nm. The emission spectrum was recorded by an LS-45 luminescence
spectrometer (PerkinElmer Inc., Waltham, MA) with excitation at 450 nm and emission
from 470 to 500 nm, and the integrated area under the emission curve is indicative of the
amount of β-sheet structures in solution. To accurately record the ThT fluorescence
induced by binding of β-sheet structures, the background fluorescence of ThT alone is
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subtracted from each reading. Fibril formed in this fashion was stored at 4 ºC for up to 2
weeks.
2.5 ThT Competition Assay
It has been reported that some aromatic small molecules can disrupt the binding of
ThT to β-sheet structure and cause a decrease in ThT fluorescence [35,39] which results in
an incorrect representation of Aβ aggregation extent in the presence of aromatic
compounds. To evaluate the viability of applying ThT fluorescence measurement for
monitoring Aβ monomer aggregation under the effects of compounds, it is necessary to
conduct a ThT competition assay. Pre-formed fibrils were incubated alone or in the
presence of compounds at 25 ºC for 15 min. Then, ThT fluorescence was measured and a
reduction of fluorescence relative to control indicates that ThT binding sites on fibrils’ βsheet structure were disrupted by the compounds, and thus Aβ aggregation extent would
be underestimated if using ThT fluorescence as an indicator.
2.6 Aβ40 Fibril Dissociation
Aβ40 fibril was prepared following the method described in Section 2.4. 20 µM
fibril was mixed with desired concentration of compound in 40 mM Tris-HCl and
incubated at 25 ºC with continuous agitation on vortex (500 rpm). 4 µL of reaction sample
was taken periodically to be examined in dot blot assay in the same manner as described
in Section 2.3.1.
2.7 Transmission Electron Microscopy
Transmission electron microscopy (TEM) is a common technique used to visualize
the morphology of protein aggregates based on a beam of electrons transmitting through
specimen and subsequently interacting with the specimen to form a high resolution image.

18

20 µL aliquots of the aggregation reactions at selected time points were placed onto 300square mesh formvar-carbon supported copper grids (Electron Microscopy Science,
Hatfield, PA) for 3 min to allow samples to adsorb onto the grids. The excess sample
solution was wicked away, and the grid was allowed to air dry for 3 min. This process was
repeated a total of 3 times to ensure that the grids contain a sufficient quantity of samples
for visualization. Then, 20 µL of 2 % uranyl acetate was placed on each grid and wicked
away after 8 min. Uranyl acetate is a negative stain, which stains background so that it
appears dark in images, while the specimen remains unstained and light. The grids were
left under a fume hood overnight to dry. The dried grids were visualized using a JEOL
200CX transmission electron microscope (JEOL, Peabody, MA) at 120kV.
2.8 Preparation of Aβ42 Oligomer
Aβ42 monomer was used for preparation of oligomer because this isoform of Aβ
protein can aggregate into more stable oligomer at lower concentrations compared with
Aβ40. Aβ42 monomer was dissolved in DMSO to yield a 1.5 mM Aβ42 stock solution. This
stock solution was combined with 10 mM DMSO-dissolved compound. The solution was
then diluted in phosphate buffer containing NaCl to yield a solution with final
concentrations of 15 µM Aβ42 monomer, 150 µM compound and 1 µM NaCl. The reaction
mixture was incubated at 25 ºC without agitation for 30 min. Oligomer formed was used
immediately for Western blot (Section 2.8) after the addition of 0.1% Tween 20 or used
for ANS fluorescence measurement (Section 2.9) without the addition of Tween.
2.9 Aβ42 Oligomer Size Analysis by SDS-PAGE with Western Blot
SDS-polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting
with Aβ-specific antibody is a widely used method for separating and detecting Aβ species
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based on their size [40]. Aβ42 oligomer solutions formed in the absence (control) or
presence of compounds were mixed with Laemmli buffer (1:1), and 12 µL of each sample
was loaded onto a 4-20 % Tris-HCl gel (Bio-Rad, Hercules, CA). Precision-Plus protein
standard was loaded in parallel to indicate molecular weight. The gel electrophoresis was
carried out at 120 V for 60 min, and proteins on the gel were transferred onto a 0.2 µm
nitrocellulose membrane (Bio-Rad, Hercules, CA) at 14 V for 12 min via semi-dry blot
transfer on a Trans-blot SD semi-dry transfer cell (Bio-Rad, Hercules, CA). The membrane
was then blocked overnight at 4 ºC with blocking buffer (5 % nonfat milk in PBST). After
a PBST wash, the membrane was incubated with primary antibody 6E10 (1:1000) in
blocking buffer for 1 h, shaking at 25 ºC. As a sequence-specific antibody, 6E10 can bind
to the N-terminal region of all Aβ42 species independent of their size and conformation.
The membrane was then washed with PBST and incubated with HRP-conjugated goat antimouse IgG antibody (1:2000) and Precision Protein StrepTactin-HRP conjugate (1:5000)
in blocking buffer for 45 min, shaking at 25 ºC. The Western blot image was acquired via
a Bio-Rad ChemiDocTM XRS+ image system, and quantitative analysis of band density
was performed using Bio-Rad Image LabTM software.
2.10 Aβ42 Oligomer Conformation Analysis with ANS Fluorescence
8-Anilino-1-naphtalenesulfonic acid (ANS) is a fluorescent probe which has been
used to examine the structural properties of Aβ42 oligomer [41,42]. ANS has a blue shifted
emission spectrum and an increased fluorescence intensity when binding to exposed
hydrophobic regions on protein surfaces. Thus, Aβ42 oligomer exhibiting a higher ANS
intensity has higher surface hydrophobicity. 50 mM DMSO dissolved ANS solution was
added to Aβ42 oligomer formed in the presence or absence (control) of compounds (as
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described in Section 2.6) to yield a final concentration of 1 µΜ Aβ42, 10 µΜ compound,
and 50 µΜ ANS. The ANS emission spectrum was recorded by an LS-45 luminescence
spectrometer with excitation at 350 nm and emission from 400 to 600 nm, and the
integrated area under the emission curve with background subtraction represents the ANS
intensity value of Aβ42 oligomer.
2.11 Preparation of Aβ40 Soluble Aggregate
SEC-isolated Aβ40 monomer was diluted to 100 µM in 40 mM Tris-HCl. With the
addition of 1-10 mM of NaCl and continuous agitation by vortexing (800 rpm), the
aggregation process was initiated and promoted. Aggregation was monitored by measuring
ThT fluorescence. As aggregation progressed, the reaction solution became a
heterogeneous system which was a mixture of unreacted monomers, desired soluble
aggregates, and mature fibrils. The reaction solution was first centrifuged (14,000 rpm, 15
min) to separate monomers and soluble aggregates from fibrils (which precipitated as a
pellet). Soluble aggregates were subsequently separated from monomers by SEC isolation
on a Superdex 75 column, where soluble aggregates eluted in the volume of 8-10 mL, as
shown in Figure 2.1B. The concentrations of SEC-isolated Aβ40 soluble aggregates were
determined from UV absorbance (276 nm), corrected for light scattering, and respective
ThT fluorescence measurements were recorded. The size of soluble aggregates was
measured by DLS. The soluble aggregates obtained in this manner has an average
hydrodynamic radius (RH) of around 100 nm. Aβ40 soluble aggregates were stored at 4 ˚C
for up to 3 days. Upon further use, ThT fluorescence measurements were taken to correct
for changes in concentrations, and DLS measurements were taken to validate the changes
in size were minimal.
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2.12 Aβ40 Soluble Aggregate Association Monitored by DLS
Aβ40 soluble aggregates in a high ionic strength buffer and the absence of monomer
undergo an association process in which they increase their size by lateral interaction with
one another, and this size increase can be monitored by measuring the RH changes via DLS.
The association process was monitored by recording changes in RH instead of light intensity
because the monodisperse property of SEC-purified Aβ40 aggregate allows a consistent and
accurate RH measurement. SEC-isolated Aβ40 soluble aggregate was diluted in 40 mM TrisHCl in the absence (positive control) or presence of desired concentration of compounds.
Association was initiated by the addition of 150 mM NaCl. 12 µL of sample was loaded in
DLS cuvette for a continuous measurement of RH. The reaction sample without the addition
of NaCl was served as a negative control to ensure the stability of soluble aggregate.
Results were plotted as changes in RH versus time. The association rate was defined as the
slope of the linear regression of this plot, and a relative association rate was obtained by
normalizing each compound-containing sample’s association rate to that of the positive
control.
2.13 Aβ40 Soluble Aggregate Elongation Monitored by QCM
The quartz crystal microbalance (QCM) is a sensitive, robust, real-time technique
for the measurement of surface-specific changes in mass with minimal interference from
chemical tags or other artifacts. This technique has been applied widely in the field of
biotechnology, such as the detection of DNA, evaluation of protein interactions, and
quantification of liposome vesicle immobilization [43]. QCM utilizes the piezoelectric
property of quartz crystals, which enables a conversion between electricity and stress
applied on the crystals. When a crystal is placed in an alternating electric field at its
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fundamental frequency, it oscillates at a characteristic frequency, and this frequency can
be constantly measured and recorded. Oscillation frequency changes (Δf), as the mass is
deposited on the crystal, in a way that linearly related to the mass change (Δm) through
Sauerbrey’s equation (Eq. 2.3).
Δ4 =

5%67 8
9 :; <;

Δ=

Eq. 2.3

Thus, by continuously recording the crystal’s oscillation frequency change, the
real-time mass change corresponding to addition of monomer onto immobilized growing
aggregates can be sensitively measured. In Sauerbrey’s equation, the proportionality
coefficient is a function of the quartz crystal (Inficon, East Syracuse, NY) properties, in
which, fo is the fundamental resonant frequency of the crystal (9 MHz), A is the crystal’s
active surface area (34.19 mm2), ρq is the density of quartz (2.65 g/cm3), and µq is the shear
modulus of quartz, (2.947·1011 g/cm·sec2). One assumption underlying Sauerbrey’s
equation is that viscoelastic effects are negligible, and this assumption can be verified if
the dissipation change (∆D) to frequency change (∆f) ratio is less than 10-5 Hz-1. Dissipation
can be calculated by QTZ software (Resonant Probes, Goslar, Germany) [44]. In this case,
the sample can be considered sufficiently rigid and the effect of viscoelasticity is minimal
to the system.
Using QCM to measure Aβ40 soluble aggregate elongation with Aβ40 monomer
involves two steps: first, soluble aggregate was immobilized on the crystal surface through
amino-coupling chemistry; second, monomer was introduced into the system and
elongated on bound aggregate, as shown in Figure 2.3A.
The first step to immobilize Aβ40 soluble aggregate on the gold sensing electrode
of AT-cut polished quartz crystal was accomplished by functionalizing the crystal surface
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with avidin protein. First, the top gold electrode was exposed to 5 mM DDP for 20 min for
the formation of thiol linkages with the gold surface. Then, the electrode was washed with
DI water and incubated with 300 µL 100 mg/mL NHS and 200 µL 100 mg/mL EDC for
another 20 min. This step activates the crystal to form reactive sites by interactions between
the N-hydroxy group of NHS and the bound carboxyl group. After rinsing with DI water,
the electrode surface was incubated with 0.2 mg/mL avidin in 100 mM HEPES for 1 h to
allow covalent binding of avidin to the crystal by displacing a succinimide group with a
primary amine group in avidin. Finally, the electrode was rinsed with DI water and
incubated with 2.7 M triethylene glycol monoamine to block any remaining active
succinimide sites to minimize the non-specific binding in later use. The avidinfunctionalized crystal was stored in 40 mM Tris-HCl and used within 3 days.
Upon use, the functionalized crystal was placed in a flow cell which was connected
to a high-precision reciprocating piston pump equipped with a switching valve, as shown
in Figure 2.3B. By injecting sample solution into a loop and pumping solution into the flow
cell at a predefined flowrate, the disturbance on crystal’s baseline frequency due to the
addition and removal of solution over the crystal was avoided.
After placing the functionalized crystal in the flow cell, Aβ40 soluble aggregate
immobilization on the crystal surface was completed by following two steps. First, 1000
µL of 5.5 µM biotinylated Aβ40 monomer was introduced into the flow cell to be
immobilized on the avidin-functionalized crystal via avidin-biotin coupling. Then,
unlabeled Aβ40 soluble aggregate was injected into the flow cell and captured by the
previously bound Aβ40 monomer.
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To measure elongation, a desired concentration of unlabeled Aβ40 monomer was
introduced into the system, and this process was continuously monitored by measuring the
mass increase. For the purpose of investigating the effects of compounds on elongation,
desired concentration of compound was first injected into the system before monomer
addition to allow free binding on Aβ40 soluble aggregate. A subsequent injection of Aβ40
monomer for elongation on compound-bound soluble aggregates reflects the effect of
compounds on elongation. Results were plotted as changes in mass versus time. The
elongation rate was defined as the slope of the linear regression of this plot, and relative
elongation rate was obtained by normalizing each compound affected elongation rate to
the elongation rate observed in the absence of compound.
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Figure 2.1 FPLC-SEC purification profile for Aβ40 monomer and Aβ40 soluble
aggregate. Aβ40 monomer was eluted at the volume of 12-15 mL (panel A), and Aβ40
aggregate was eluted at the volume of 8-10 mL (panel B).
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Figure 2.2 DLS configuration and schematic representation of a speckle pattern [38]. (A) A beam of incident light
generated by a laser illuminates the sample in a cell. The incident light’s intensity can be adjusted by an attenuator. Light
is scattered in all directions by particles within the sample, and a detector is located at a right-angle to collect the scattered
light intensity information. The computer employs the Cummulant analysis method to transfer raw data into
hydrodynamic radius, RH. (B) The bright spots and the dark spots of speckle pattern are a result of scattered light
destructive and constructive additions
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Figure 2.3 Aβ40 soluble aggregate elongation monitored by QCM. (A) The avidin biotin chemistry was used to couple
Aβ40 aggregate to the surface and unlabeled Aβ40 monomer was captured by the previous bound aggregate through
elongation. (B) Quartz crystal was placed in flow cell which was connected with a pump (controlled by a PC) through an
injection valve. Crystal frequency was monitored with the QCM network analyzer (controlled by another PC).

CHAPTER 3
EFFECT OF RESVERATROL AND DERIVATIVES ON MODULATING AMYLOIDβ AGGREGATION AND ALTERING THE MORPHOLOGY OF AGGREGATES
3.1 Introduction
Identifying small molecules capable of inhibiting Aβ aggregation is one potential
route in developing an AD prevention, treatment and cure based on the fact that Aβ
aggregate species, not Aβ monomers, cause neurotoxicity. An Aβ fibril model established
by Petkova and colleagues [45] based on solid state nuclear magnetic resonance (NMR)
data illustrated a structure in which each Aβ peptide forms two parallel β-sheets by residues
12-24 and 30-40. Residues between these two β-sheets form a β-turn that bends the peptide
and brings the two β-sheets in contact through sidechain-sidechain interactions, such as the
salt bridge formed between residue D23 and residue K28. Since the core of Aβ fibrils are
residues 12-40, Aβ40 and Aβ42 monomers aggregate into fibrils in almost the same manner.
Aβ42 monomers, however, form more stable oligomers and were thus used to study
oligomerization. Other Aβ aggregation mechanistic steps, soluble aggregate elongation,
soluble aggregate association and fibril formation, were investigated using Aβ40 peptide.
Based on this model, small molecules that can disrupt hydrogen bonding, sidechain
interactions, or hydrophobic interactions of Aβ aggregates are potentially capable to inhibit
or alter aggregation process, and polyphenols is one class of molecules that have shown
such effects toward Aβ aggregation. The multiple aromatic rings in these polyphenols were
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hypothesized to play an important role in breaking the hydrophobic interactions since they
can interact with the two phenylalanine residues at position 19 and 20 via p-p stacking
interactions. The hydroxyl groups on the polyphenols were also believed to be important
because they can interfere with hydrogen bonding of the aggregates. In this chapter,
resveratrol (RES), piceatannol (PIC), oxyresveratrol (OXR) and piceid (PID) were
introduced into various mechanistic steps of Aβ aggregation with their effects on each
aggregation step evaluated. As shown in Figure 3.1, all the compounds have two phenyl
rings linked by a two-carbon bridge with 3-4 hydroxyl groups at different positions (RES,
PIC and OXR) or a replacement of a hydroxyl group with a glucoside (PID).
Compared with larger molecules, small molecules have the advantage of
penetrating the blood-brain barrier more easily. In general, to cross this barrier, molecules
need to be lipophilic and smaller than 500 Da in size. RES and its derivatives investigated
in this study have molecular weights ranging from 228 to 390 Da. In addition, within the
ChemAxon database their logP values range from 1.13-3.4. LogP is a quantity to express
partition coefficient between water and octanol, and a LogP less than 5 represents a
lipophilic compound. Therefore, RES and derivatives studied here should potentially be
able to pass through the blood-brain barrier. In fact, resveratrol’s abilities to penetrate the
blood-brain barrier and induce beneficial physiologic responses have been supported by
human clinical trials [46,47]. It is possible that resveratrol’s neuroprotective property is
related to its interaction with Aβ aggregation and thus it was investigated in this chapter.
To further understand the key molecule structures in inhibiting and altering Aβ
aggregation, resveratrol’s derivatives were also studied.
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3.2 Materials and Methods
3.2.1 Preparation of Resveratrol and Derivatives
RES, PIC, OXR and PID were purchased from TCI America (Portland, OR). RES,
PIC and PID were stored at 4 ºC, and OXR was stored at -20 ºC. All compounds were
dissolved in DMSO at a concentration of 10 mM immediately prior to use to prevent
structural changes induced by storage in solvent.
3.2.2 ThT Competition Assay
As described in Section 2.5, pre-formed fibrils were diluted to 2.5 µM alone
(control) or in the presence of 12.5 µM compounds and incubated at 25 ºC for 15 min. With
the addition of 10 µM ThT, fluorescence was measured and compared to that of control.
3.2.3 Aβ40 Monomer Aggregation
To evaluate the overall inhibitory capabilities of resveratrol and derivatives,
monomer aggregation assays were conducted using dot blot monitoring technique as
described in Section 2.3.1 with the inclusion of 100 µM resveratrol and derivatives.
Furthermore, Aβ40 monomer aggregation under the effect of PIC was monitored using DLS
as described in Section 2.3.2.
3.2.4 Aβ40 Fibril Dissociation
Aβ40 fibril dissociation was performed as described in Section 2.6 with the addition
of 100 µM resveratrol and derivatives.
3.2.5 Transmission Electron Microscopy
TEM was utilized to evaluate the morphological changes of aggregates induced by
the presence of resveratrol and derivatives. The end product samples of Aβ40 monomer
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aggregation (Section 3.2.3) and Aβ40 fibril dissociation (Section 3.2.4) were prepared and
imaged as described in Section 2.7.
3.2.6 Aβ42 Oligomerization and Characterization
Aβ42 oligomerization was performed as described in Section 2.8 in the absence
(control) or presence of 150 µM resveratrol and derivatives. After 30 min incubation,
oligomers formed were used immediately for size analysis via SDS-PAGE and Western
blot as described in Section 2.9 after the addition of 0.1% Tween 20 or used for
conformation analysis via ANS fluorescence as described in Section 2.10 without the
addition of Tween.
3.2.7 Aβ40 Soluble Aggregate Association
Aβ40 soluble aggregate was prepared as described in Section 2.11. Soluble
aggregate association was performed as described in Section 2.12 with 2 µM soluble
aggregate. Association was initiated by the addition of 150 mM NaCl in the absence
(control) or presence of 50 µM resveratrol and derivatives.
3.2.8 Aβ40 Soluble Aggregate Elongation
Inhibition of Aβ40 soluble aggregate elongation was assessed as descried in Section
2.13. Elongation was initiated by the introduction of 30 µM monomer to 2 µM soluble
aggregate that was in exposure to 300 µM resveratrol and derivatives, or not (control).
3.3 Results
3.3.1 RES, PIC, and OXR Interfere with ThT Binding to Aggregate β-sheet Structure
Some aromatic molecules have capabilities to disrupt the binding between ThT and
Aβ aggregates by competing with ThT for the binding sites on Aβ aggregates. Thus, the
presence of such compounds can lower ThT fluorescence of Aβ aggregates compared with
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that of Aβ aggregates alone. In this case, using ThT fluorescence as the technique for
monitoring Aβ aggregation would underestimate the aggregation extent and could lead to
a false positive for Aβ aggregation inhibition. In order to assess this potential complication,
resveratrol and derivatives’ ability to interfere with ThT fluorescence was investigated, and
results are shown in Figure 3.2. Incubation of Aβ fibrils with RES, PIC and OXR resulted
in a significant reduction of ThT fluorescence, with relative fluorescence values of 70±6
%, 58±1 % and 75±13 %, respectively. PID, on the other hand, does not alter ThT binding
with Aβ aggregates. Since the majority of compounds in this study interfere with ThT
binding, it would be misleading to monitor Aβ aggregation utilizing ThT fluorescence. As
a result, an alternative approach to evaluate Aβ aggregation was employed: dot blot with
immunocytochemistry. In dot blot assay, a conformational specific antibody, LOC, which
only recognizes aggregated not monomeric Aβ species, was utilized for monitoring
aggregation extent.
3.3.2 PIC Reduces LOC Dot Blot Intensity in Aβ Monomer Aggregation
As described in Section 1.3, there are three phases in the Aβ aggregation process:
a rate-limiting lag phase in which aggregation nuclei are formed; a growth phase in which
monomers interact with nuclei causing the sizes of intermediate aggregates to increase
rapidly and β-sheet structures to form; and a plateau phase in which monomers, soluble
aggregates and fibrils exist in equilibrium. When aggregation is monitored with LOC
antibody and dot blot, an aggregation growth curve with these three distinct phases is
observed (Figure 3.3).
Polyphenols can potentially interfere with aggregation in two ways: reducing the
aggregation plateau, expressed as relative plateau (the ratio of aggregation plateau in the
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presence of compound to that of control), or extending the time of lag phase, expressed as
relative lag (the ratio of lag time in the presence of compound to that of control). Aβ40
monomer aggregation in the presence of stilbenes was performed, and results are shown in
Figure 3.3. When aggregation growth curves were obtained (Figure 3.3B), the presence of
RES, OXR and PID in the aggregation process did not significantly extend the lag phase
nor reduce the plateau (Figure 3.3C). In contrast, PIC substantially altered aggregation, as
evidenced by a complete absence of LOC intensity as aggregation progresses (Figure 3.3B,
C).
3.3.3 PIC Reduces LOC Dot Blot Intensity of Pre-formed Aβ Fibrils
To additionally explore the possibility that PIC can disrupt Aβ fibrils after
aggregation has occurred, pre-formed Aβ fibrils were incubated alone (control), or with
resveratrol and derivatives. Samples periodically dotted for LOC antibody detection
(Figure 3.4A). In the first 2 h, there were no noticeable variations in LOC intensity,
representing that all samples started with mature Aβ fibrils rich in β-sheet structure.
However, after 5.5 h, fibrils incubated with PIC started to lose their binding affinity with
LOC, as evidenced by a decreased LOC intensity, while no such changes were observed in
other samples. At 26 h, PIC significantly reduced LOC intensity to as low as 3 % of control
(Figure 3.4B). The slow time course for the observed changes in LOC binding suggests
that PIC does not compete with LOC for the same binding sites on Aβ aggregates, but
suggests that PIC may dissociate aggregates.
3.3.4 PIC Induces Aβ Aggregate Conformational Change
The observed PIC-induced changes in LOC intensity may result from the ability of
PIC to inhibit fibril assembly and dissociate fibrils. Alternatively, these observations may
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result from the ability of PIC to disrupt aggregate conformation and thus LOC binding. To
differentiate between these possibilities, a non-conformational dependent technique, DLS,
was used to monitor Aβ aggregation under the effect of PIC. DLS measures the scattered
light intensity change, which correlates with the overall dynamic size and quantity of Aβ
aggregation species. Distinct from growth curves obtained from dot blot, light intensity
increased and then stabilized for the sample incubated with PIC, resulting in a growth curve
with three phases, similar to the control (Figure 3.5A). While PIC was unable to extend the
lag time, it significantly reduced plateau to 55±9 % of control (Figure 3.5B). The
discrepancy between a complete plateau reduction in the conformational dependent method
(LOC) and a partial plateau reduction in this non-conformational dependent method (DLS)
indicates that PIC does not abolish aggregation, but instead induces an aggregate
conformational change that alters LOC binding.
To further explore this hypothesis, TEM was used to visualize aggregates formed
following monomer aggregation in the presence of PIC and other resveratrol derivatives
(Figure 3.6A) as well as pre-formed fibrils incubated with resveratrol and derivatives
(Figure 3.6B). Aβ fibrils exhibit a straight, long and stacked rod-shape morphology. In
TEM images of both Aβ aggregates formed in the presence of PIC and Aβ fibrils incubated
with PIC, fibrils could be identified, providing further support for the hypothesis that PIC
induced a conformational change. Moreover, stilbenes studied in this work all induced
some variations for the morphology of Aβ fibrils from their typical structure, and changes
induced by PIC remained the most pronounced.
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3.3.5 Effects of RES and Derivatives on Aβ Oligomers Size Distribution and Surface
Hydrophobicity
To investigate the step along the aggregation pathway where compounds intervene,
Aβ oligomerization was performed to examine the effect of resveratrol and derivatives in
the earlier stages of aggregation. Since oligomers are small in size and may lack β-sheet
structures, common size-dependent methods (DLS), or β-sheet-dependent methods (ThT
fluorescence and LOC antibody detection) cannot be readily used for evaluating
compounds’ effect on oligomers. Thus, SDS-PAGE with Western blot probed by sequence
specific 6E10 antibody was utilized for analyzing oligomers’ size distribution (Figure
3.7A). Resveratrol and derivatives failed to alter the quantity of both smaller oligomers
(25-100 kDa, closed bars) and larger oligomers (100-250 kDa, open bars).
To further probe oligomer conformational changes, stilbenes’ capability in altering
Aβ oligomer conformation was assessed using ANS fluorescence (Figure 3.7C). ANS is
commonly used as a probe to study proteins’ conformational changes. This dye increases
fluorescence when bound to hydrophobic regions on the protein surface. Thus, differences
in ANS fluorescence indicate conformation differences. Oligomers formed in the presence
of PIC exhibited the most substantial reduction in ANS fluorescence to as low as 53±6 %
of control, indicating a reduced surface hydrophobicity of oligomers and conformational
change. RES was also able to reduce ANS fluorescence to 76±5 % of control. In contrast,
the other two compounds exhibited no significant effects. The observation of surface
hydrophobicity change for oligomers formed in the presence of PIC provides further
support for the ability of PIC to alter Aβ aggregates’ conformations. Further, these changes
might occur early in the aggregation process.
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3.3.6 RES and Derivatives Selectively Inhibit Mechanistic-Specific Growth of Aβ
Soluble Aggregates
To determine whether stilbenes can intervene at intermediate stages of aggregation,
Aβ soluble aggregates were isolated and stimulated to grow in size by two mechanisms:
association, in which Aβ soluble aggregates increase in thickness via lateral interaction,
and elongation, in which Aβ soluble aggregates increase in length via monomer addition.
Aβ soluble aggregate association was initiated by addition of physiological salt to isolated
intermediates and evaluated by measuring changes in Aβ aggregates’ hydrodynamic radius
using DLS (Figure 3.8). PIC inhibited association with a decreased association rate as low
as 9±0.5 % of control. In contrast, PID promoted association with an increased association
rate as high as 143±6 % of control. Aβ soluble aggregate elongation was initiated by the
introduction of monomer across a quartz crystal surface onto which Aβ isolated
intermediates were immobilized. Elongation was evaluated by measuring changes in the
deposited mass on crystal (Figure 3.9). PIC again showed inhibition in elongation (53±4
%), but the inhibition effect was similar to that induced by OXR (64±9 %) and PID (45±7
%). In contrast, RES promoted elongation by increasing the elongation rate to 140±16 %
of control. These results indicate that different stilbenes all intervene with intermediate
stages of Aβ aggregation but they affect different mechanistic steps of soluble aggregates
growth distinctly.
3.4 Discussion
Stilbenes investigated in this study are natural small molecules widely found in
food and drinks, such as grapes and red wine. Their antioxidant, anti-inflammatory nature
has made them promising pharmaceutical candidates for various diseases, including

37

neurodegenerative diseases and cancers [21]. AD is a complex, multi-factorial disease
which involves Aβ peptide aggregation and its subsequent events such as oxidative stress
and inflammatory response. With resveratrol and derivatives’ antioxidant, antiinflammatory and anti-aging effects documented in other studies [21,25,48,49], their
capabilities of intervening with Aβ aggregation were determined in this study. Results
demonstrate that stilbenes, and PIC in particular, may act as natural therapeutics that not
only attenuate downstream damaging events but also target the underlying cause of the
disease, Aβ aggregation.
Aβ aggregation is a process in which non-toxic monomeric Aβ peptides assemble
into insoluble aggregated fibrils that accumulate and deposit among AD patients’ neurons.
Compounds that could bind to Aβ aggregates have the potential to disturb the aggregation
process and, furthermore, modulate the production of toxic aggregates. This study shows
that PIC has the most profound effect on reducing aggregation detected by LOC binding
(Figure 3.3). Moreover, when pre-formed Aβ aggregation products, Aβ fibrils, were
exposed to PIC, PIC again substantially reduced LOC binding (Figure 3.4). Conversely,
RES, OXR and PID did not induce any significant difference, either when they were
present during aggregation or when they were introduced to pre-formed aggregates. There
are two possible interpretations for the interactions between PIC and Aβ peptide. PIC could
halt the propensity of Aβ monomer self-assembly and dissociate pre-formed aggregates.
Alternatively, PIC could disrupt Aβ aggregates’ structure in a way that prohibits
recognition by LOC antibody.
Monitoring Aβ aggregation via DLS and visualizing Aβ fibrils via TEM support
the explanation that the complete loss of LOC intensity in the presence of PIC was a result
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of an aggregates’ conformational change. In the presence of PIC, Aβ aggregation follows
a similar growth curve compared with control, although reaching a lower plateau,
demonstrating that aggregates are formed (Figure 3.5). This result was confirmed by the
existence of visible fibrils under TEM. Moreover, fibrils formed in the absence or presence
of PIC showed significant morphology differences (Figure 3.6A). These two techniques
independently demonstrated that the change PIC induced in Aβ aggregation is not a
complete inhibition, but a modulation of Aβ aggregation that involves Aβ aggregate
conformational change. It has been established that modifying the surface structure of Aβ
aggregates, causing changes of electrostatic and hydrophobic interactions with neurons,
may be one way to alter cytotoxicity [50]. A study investigating the possible protective
effects of PIC on Aβ-induced PC12 neuronal cell death found that PIC exerted much
stronger protective effects than RES did [51]. Thus, the intervention of PIC with Aβ
aggregate might be potentially beneficial for AD patients.
Highly effective therapeutic compounds may intervene with multiple aggregation
mechanisms, and a combination of compounds working at different steps may create a
more effective therapeutic agent. Thus, the action of these compounds along the
aggregation pathway was explored. Oligomerization is the rate-limiting process in which
Aβ monomers cluster together to form small aggregates. Western blots showed that none
of the compounds could reduce the quantity of oligomers in both large (100-250 kDa) and
small (25-100 kDa) size ranges (Figure 3.7A and Figure 3.7B). This result corresponds to
the inability of compounds to alter lag time in aggregation assays. However, PIC is able to
alter oligomer surface hydrophobicity, evidenced by a decreased ANS fluorescence. This
result further supports PIC-induced changes in aggregate conformation and indicates that
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conformational changes are induced very early in the aggregation process. In addition, RES
also had a similar effect on ANS binding but to a lesser extent. These observed
conformational changes of reduced oligomer surface hydrophobicity are potentially
beneficial, since proteins with highly hydrophobic surfaces more readily interact with
biological membranes and cause toxic effects [52,53].
When intermediate steps within the aggregation pathway were examined, PIC
significantly reduced the lateral association of soluble aggregates, and PID significantly
promoted association, while RES and OXR had no effect. In contrast, all compounds were
able to affect elongation of soluble aggregates by monomer addition. RES promoted
elongation, while PIC, OXR and PID reduced elongation. PIC, however, is the only
compound able to inhibit both mechanisms. This result indicates that resveratrol and
derivatives can impact the later stages of aggregation, but interfere with the processes in
distinct manners. The collective effects of resveratrol and derivatives on different stages of
Aβ aggregation may be the underlying reason for Aβ aggregates’ morphology alterations
observed under TEM (Figure 3.6).
In summary, this study demonstrated that resveratrol and derivatives all exhibit
capability in intervening with Aβ aggregation. These compounds are able to alter the
morphologies of Aβ aggregates, and this effect is a result of their involvement in multiple
stages of aggregation. Among all compounds evaluated here, PIC exhibited the most
pronounced effect in various mechanisms along aggregation pathway. This superior
inhibitory capability might be attributed to its unique structure among compounds – a
catechol moiety formed by two adjacent hydroxyl groups on ring B (R5 and R6), as shown
in Figure 1.2. Study has shown that the hydrogen transfer from the hydroxyl groups on ring
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B is more favored than the hydroxyl groups on ring A because of the resonance effects in
the radical products [54]. Also, particularly, the hydrogen transfer from the R5 hydroxyl
group is the most favored in water medium due to larger stabilization of the resultant
phenoxyl radical [55]. Moreover, the presence of the catechol moiety provides a larger
stabilization of the radical formed by hydrogen transfer from the R5 group [56]. Together,
these findings support PIC’s more effective intervention in Aβ aggregation than other
compounds evaluated in this study.
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(Resveratrol, RES)

(Piceatannol, PIC)

(Oxyresveratrol, OXR)

(Piceid, PID)

Figure 3.1 Structure of resveratrol and derivatives. RES and three selected derivatives
are all highly conjugated systems composed of two phenyl rings linked by a two-carbon
bridge. RES has three hydroxyls while selected derivatives vary by one additional hydroxyl
(PIC and OXR) or a glucoside in place of one of the hydroxyls (PID).
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Figure 3.2 Effect of resveratrol and derivatives on ThT fluorescence with Aβ40 fibrils.
2.5 µM pre-formed Aβ40 fibril was incubated, at 25 ºC for 15 min, alone (CONT) or with
12.5 µM RES, PIC, OXR and PID in 40 mM Tris-HCl. Samples were then mixed with 10
µM ThT. ThT fluorescence was measured for each sample, and relative fluorescence was
expressed as a percentage of that of control. Error bars represent SEM, n=4. **p<0.01,
***p<0.001, versus control.
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Figure 3.3 Effect of resveratrol and derivatives on Aβ40 monomer aggregation. 20 µM
SEC-purified Aβ40 monomer was aggregated alone (CONT, ) or in the presence of 100
µM RES ( ), PIC ( ), OXR ( ), or PID ( ). (A) Extent of aggregation was evaluated
by dot blot using LOC antibody detection. (B) LOC intensity for each dot was quantified
and normalized to the intensity of control’s plateau. Results are representative of four
independent experiments. (C) Plateau reduction capability was evaluated as relative
plateau, or the plateau observed in the presence of compound normalized to the control
plateau. Error bars represent SEM, n=4. ***p<0.001, versus control; ++p<0.01,
+++p<0.001, between samples.
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Figure 3.4 Effect of resveratrol and derivatives on pre-formed Aβ40 fibrils. 10 µM Aβ40
fibril was incubated alone (CONT) or with 100 µM RES, PIC, OXR, or PID. (A) Samples
were taken periodically and evaluated by dot blot using LOC antibody. (B) After 26 h of
incubation, the LOC pixel intensity of fibrils incubated with compounds was normalized
to the intensity of control. Error bars represent SEM, n=4. ***p<0.001, versus control;
+++p<0.001, between samples.
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Figure 3.5 Effect of PIC on Aβ40 monomer aggregation monitored via DLS. 20 µM
SEC-purified Aβ40 monomer was aggregated alone (CONT,
) or in the presence of 100
µM PIC ( ). (A) Aggregation was measured as the scattered light intensity. (B) The
plateau intensity for aggregation in the presence of PIC was compared with control. Error
bars represent SEM, n=3.
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Figure 3.6 Effect of resveratrol and derivatives on Aβ40 fibril structure. (A) Aβ40 fibril formed by aggregation of 20 µM
monomer in the absence (CONT) or presence of 100 µM resveratrol and derivatives. Samples were grided when the control reaction
reached the equilibrium plateau. (B) 20 µM pre-formed Aβ40 fibril was incubated alone (CONT) or with 100 µM resveratrol and
derivatives for 26 h before samples were gridded and visualized via TEM. Images are representative of three independent
experiments. Scale bars represent 100 nm.
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Figure 3.7 Effect of resveratrol and derivatives on Aβ42 oligomer size distribution and
surface hydrophobicity. 15 µM Aβ42 monomer was subjected to oligomerization
conditions alone (CONT) or with 150 µM resveratrol and derivatives. (A) Oligomerization
products were resolved by SDS-PAGE and Western blot and probed using 6E10 antibody.
(B) Adjusted volume intensity of aggregate species of 25-100 kDa (closed bars) and 100250 kDa (open bars) is reported relative to control (CONT). Error bars represent SEM,
n=4. (C) ANS solution was added to Aβ42 oligomer formed in the absence (CONT) or
presence of resveratrol and derivatives to yield a final concentration of 1 µM Aβ42, 10 µM
compound, and 100 µM ANS. ANS fluorescence was measured and integrated from 450
to 550 nm. Result is reported relative to control (CONT). Error bars represent SEM, n=4,
***p<0.001, versus control.
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Figure 3.8 Effect of resveratrol and derivatives on Aβ40 soluble aggregate association.
2 µM SEC-purified Aβ40 soluble aggregates were incubated alone (CONT, ) or in the
presence of 50 µM RES ( ), PIC ( ), OXR ( ), or PID ( ). Association was initiated
by the addition of 150 mM NaCl. Incubation of soluble Aβ40 soluble aggregates in the
absence of NaCl served as a negative control ( ). (A) Samples were monitored over time
by DLS for RH. (B) The rate of association was determined by linear regression. Results
are expressed as the relative association rate, or the association rate observed in the
presence of compounds normalized to the association rate of the control (indicated by the
dashed line at 1). Error bars represent SEM, n=3. ***p<0.001, *p<0.05, versus control.
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Figure 3.9 Effect of resveratrol and derivatives on Aβ40 soluble aggregates elongation.
Elongation of immobilized 2 µM SEC-purified Aβ40 soluble aggregate by monomer
addition into the QCM flow cell. (A) Crystal surfaces on which Aβ40 soluble aggregate was
immobilized were exposed to buffer (CONT, ), or 300 µM RES (
), PIC ( ), OXR
( ), or PID ( ). Elongation was initiated via subsequent introduction of 30 µM monomer.
Samples were monitored by QCM for mass change on the crystal. (B) The rate of
elongation was determined by linear regression. Results are expressed as relative
elongation rate, or the elongation rate following compound exposure normalized to the
elongation rate of the control (indicated by the dashed line at 1). Error bars represent SEM,
n=3-4. ***p<0.001, **p<0.01, *p<0.05, versus control.
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CHAPTER 4
EFFECT OF PICEATANNOL AND DERIVATIVES ON MODULATING AMYLOIDβ AGGREGATION AND ALTERING THE MORPHOLOGY OF AGGREGATES
4.1 Introduction
Our previous study demonstrated that piceatannol exerts better capabilities in
intervening with Aβ aggregation, altering Aβ aggregate conformation, and attenuating both
association and elongation, compared with resveratrol. As resveratrol’s 3’-hydroxylated
analogue, it is speculated that the additional hydroxyl group at the ortho-position might be
responsible for its superior effectiveness. This addition of one hydroxyl group also renders
piceatannol more potent than resveratrol in other aspects. Piceatannol is more readily
absorbed upon oral ingestion, has higher metabolic stability in vivo [56], and shows
enhanced endothelial nitric oxide synthase [57] and SIRT1 [58] expression. For many
biological activities, piceatannol is required in lesser quantities as compared to resveratrol
[59]. Despite the fact that piceatannol shares resveratrol’s beneficial properties, such as
anti-cancer, anti-inflammatory and anti-oxidative effects, and even surpasses resveratrol in
many aspects, it has been significantly less studied than the renowned resveratrol. A recent
query of “piceatannol” and “resveratrol” in PubMed generated 609 and 9294 results,
respectively. To better understand piceatannol’s potent effect on Aβ aggregation, this study
examined Aβ aggregation intervention of selected compounds which have similar
structures to piceatannol (Figure 4.1).
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Piceatannol’s potent effect on Aβ aggregation was purposed to be attributed to its
unique structure – two adjacent hydroxyl groups on ring B forming a catechol moiety, as
shown in Figure 1.2. To assess the above hypothesis, this study investigated compounds
that substitute piceatannol’s hydroxyl groups with methoxy groups and, as a result, break
piceatannol’s catechol structure.

By comparing methoxy derivatives’ effect on Aβ

aggregation with that of piceatannol, the role of individual hydroxyl groups could be
identified. Thus, three methoxy derivatives of piceatannol were introduced in this study,
specifically, isorhapontigenin (IRPT) and rhapontigenin (RPT), each of which replaces one
of the two hydroxyl groups of the catechol moiety on ring B with a methoxy group, as well
as 3,3’,4,5’-tetramethoxystilbene (TMS), which replaces all hydroxyl groups on
piceatannol with methoxy groups (Figure 1.2 and Figure 4.1). These compounds have
shown their therapeutic potentials for a variety of conditions. IRPT has been found in many
traditional medicinal plants, such as rhubarb [60], and many Gentum spices [61]. Its
reported bioactivities include attenuating cardiac hypertrophy [62], scavenging nitric oxide
and nitrogen dioxide radicals [63], and inducing apoptosis in human cancer cells [64]. RPT
has also been studied for its beneficial properties, such as antifungal activity [65],
antihyperlipidemic effects [32], and inhibiting angiogenesis in prostate cancer cells [66].
IRPT and RPT have been detected as piceatannol metabolites in rat plasma after rats were
injected with piceatannol [67]. TMS, the analog replacing all hydroxyl groups with
methoxy groups, is reported to have strong antiproliferative and proapoptotic activity [68].
In addition, the presence of a styrene double bond in piceatannol results in two
isomers, trans-piceatannol (trans-PIC) and cis-piceatannol (cis-PIC). Both are naturally
found in red wines. Generally, trans-PIC is more abundant, but in some variety of wines,
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cis-PIC amounts exceed that of trans-PIC [69]. Chapter 3 examined trans-PIC. In this
Chapter, cis-PIC was introduced to explore if a change of atomic arrangement would
induce a change of interactions with Aβ aggregation, since it has been experimentally
proved that the trans and cis forms of stilbenes trigger different biological effects [70,71].
Overall, this chapter is focused on determining piceatannol and its derivatives’
intervention with various mechanistic steps of Aβ aggregation. These studies not only
evaluate their therapeutic potentials for AD but also identify the key molecular structures
for effectiveness in modulating Aβ aggregation.
4.2 Materials and Methods
4.2.1 Preparation of Piceatannol and Derivatives
trans-PIC, IRPT and RPT were purchased from TCI America (Portland, OR). cisPIC was purchased from Toronto Research Chemicals, Inc. (Ontario, Canada). TMS was
purchased from Combi-Blocks, Inc. (San Diego, CA). All compounds were stored at 4 ºC
and dissolved in DMSO at a concentration of 10 mM immediately prior to use to prevent
structural changes induced by storage in solvent.
4.2.2 Aβ40 Monomer Aggregation
To evaluate the overall inhibitory capabilities of piceatannol and derivatives,
monomer aggregation assays were conducted using dot blot monitoring technique as
described in Section 2.3.1 with the inclusion of 200 µM piceatannol and derivatives.
4.2.3 Transmission Electron Microscopy
TEM was utilized to evaluate the morphological changes of aggregates induced by
the presence of piceatannol and derivatives. The end product samples of Aβ40 monomer
aggregation were prepared and imaged as described in Section 2.7.
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4.2.4 Aβ42 Oligomerization and Characterization
Aβ42 oligomerization was performed as described in Section 2.8 in the absence
(control) or presence of 150 µM piceatannol and derivatives. After 30 min incubation,
oligomers formed were stabilized by addition of 0.1% Tween 20 and used immediately for
size analysis via SDS-PAGE and Western blot, as described in Section 2.9.
4.2.5 Aβ40 Soluble Aggregate Association and Elongation
Aβ40 soluble aggregate was prepared as described in Section 2.11. Soluble
aggregate association was performed as described in Section 2.12 with 2 µM soluble
aggregate. Association was initiated by the addition of 150 mM NaCl in the absence
(control) or presence of 50 µM piceatannol and derivatives. Inhibition of Aβ40 soluble
aggregate elongation was assessed as descried in Section 2.13. Elongation was initiated by
the introduction of 30 µM monomer to 2 µM soluble aggregate that was in exposure to 300
µM piceatannol and derivatives, or not (control).
4.3 Results
4.3.1 PIC and Derivatives Modulate Aβ Monomer Aggregation
To evaluate the effect of piceatannol and derivatives on Aβ monomer aggregation,
dot blot using LOC antibody was employed to monitor the aggregation process (Figure 4.2
A). trans-PIC, consistent with the result from Chapter 3, entirely prevented the LOC
intensity increase observed for the control. cis-PIC preserved this potent effect (Figure
4.2B). IRPT and RPT were also able to reduce LOC intensity, with plateau values of 40±9
% and 74±14 %, respectively, compared to control (Figure 4.2C). TMS, however, failed to
show a significant reduction in LOC intensity. In contrast, none of the compounds affected
the aggregation lag time.
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To visually inspect changes in aggregate morphology induced by piceatannol and
derivatives, when control aggregation reached plateau phase, TEM was employed to show
morphologies of Aβ aggregates formed from monomers in the presence of piceatannol and
derivatives. trans-PIC and cis-PIC produced the most pronounced modifications on Aβ
aggregate morphology, yielding aggregates that are less fibrillary in structure and smaller
in size (Figure 4.3). IRPT and RPT reduced fibril density in a manner that paralleled
changes in LOC intensity, but these compounds exerted a limited effect on aggregate
morphology. TMS, in contrast, failed to alter either aggregate density or morphology. Thus,
both LOC-binding and TEM support a potent effect of trans-PIC and cis-PIC on the
formation of aggregates from Aβ monomer. IRPT and RPT were less effective, while TMS,
the fully methoxylated piceatannol derivative, failed to significantly modulate Aβ
aggregation.
4.3.2 cis-PIC and TMS Affect Aβ Oligomer Size Distribution
SDS-PAGE and Western blot probed with 6E10 antibody were used to evaluate the
size of Aβ oligomers formed in the absence (control) or presence of compounds (Figure
4.4A). None of the compounds altered the quantity of 25-100 kDa oligomers. trans-PIC,
IRPT and RPT also failed to alter the quantity of 100-250 kDa oligomers. In contrast, cisPIC and TMS reduced the quantity of 100-250 kDa oligomers to 27±15 % and 37±17 % of
control, respectively. Thus, cis-PIC is more effective than trans-PIC to intervene with
oligomer formation at early stages of aggregation. In addition, TMS also has a similar
effect, while compounds with a single methoxy substitution are ineffective.
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4.3.3 PIC and Derivatives Variably Affect Aβ Aggregate Association
To further understand piceatannol and derivatives’ interaction with larger Aβ
aggregates association mechanism, isolated soluble Aβ aggregates were stimulated to
associate by the addition of physiological salt in the absence (control) or presence of
compounds. The rate of increase in aggregate size was monitored by DLS (Figure 4.5A).
Results demonstrated that trans-PIC and cis-PIC reduced the association rate to 9±0.5 %
and 30±13 % of control, respectively (Figure 4.5B), while IRPT increased the association
rate to 154±19 % of control. In contrast, RPT was unable to alter Aβ aggregate association.
The effect of TMS on aggregate association could not be evaluated due to the opacity of
the TMS solution, which disturbs the diffraction of scattered light. Thus, trans-PIC and
cis-PIC had superior effects than other compounds at reducing Aβ aggregate association.
However, IRPT, a compound that replaced the R5 hydroxyl group on trans-PIC with a
methoxy group, significantly promoted association.
4.3.4 trans-PIC and cis-PIC Inhibit Aβ Aggregate Elongation
To determine if piceatannol and derivatives can inhibit the elongation of larger Aβ
aggregates, isolated soluble Aβ aggregates were immobilized onto a quartz crystal and
stimulated to elongate by the introduction of a continuous monomer flow over the crystal
surface, with or without (control) prior exposure to compounds. The rate of increase in the
mass deposited on the crystal was monitored by QCM (Figure 4.6A). trans-PIC and cisPIC, again, exhibited superior performance over other compounds by significantly
reducing the elongation rate to 53±4 % and 5±2 % of control, respectively. Methoxylated
derivatives, IRPT, RPT and TMS, lack the capability to affect elongation rate. Thus, only

56

trans-PIC and cis-PIC were able to inhibit Aβ aggregate elongation, with cis-PIC
exhibiting a more pronounced effect.
4.4 Discussion
trans-PIC has been found in common dietary foods such as blackberries [59],
grapes [72], almonds [73], peanuts [74] and passion fruit seeds [75]. It can be transported
via blood and cerebrospinal fluid by docking onto a transportation protein transthyretin
(TTR) at the thyroxine binding site [56]. Moreover, the interaction between trans-PIC and
TTR is believed to be protective against the development of AD since trans-PIC is
implicated in increasing levels of TTR [76], which can bind Aβ to prevent the formation
of large aggregates [77]. Our previous study demonstrated that trans-PIC itself was also
able to interact with Aβ peptide and modulate various Aβ aggregation mechanistic steps,
with much more potent effects than resveratrol. Thus, trans-PIC possesses strong
therapeutic potential for the prevention and treatment of AD. This study further explored
the interactions between Aβ and several derivatives of trans-PIC to show that both transPIC and cis-PIC could substantially affect Aβ aggregation, while cis-PIC had an enhanced
ability in modulating Aβ oligomerization and Aβ aggregate elongation. Results from
additional PIC derivatives indicate that the catechol moiety on ring B is important for
compounds’ effective intervention with Aβ aggregation.
Our previous work established that trans-PIC induces a complete loss of binding
affinity between LOC antibody and Aβ aggregates by changing the conformation of Aβ
aggregates. In the current study, the observation that the presence of cis-PIC during
aggregation preserves this potent effect (Figure 4.2) suggests that a geometric
rearrangement of trans-PIC’s molecules did not influence its capability to alter Aβ
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aggregate conformation. In opposition, replacing trans-PIC’s hydroxyl groups with
methoxy groups significantly weakened the effectiveness. Aggregates formed in the
presence of IRPT and RPT, which replace the R5 and R6 hydroxyl group respectively on
the ring B of trans-PIC, with a methoxy group, exhibited decreased LOC binding, but this
effect was less pronounced than that was observed for PIC. This result indicates that each
hydroxyl group within the catechol moiety is important for interventions between PIC
derivatives and Aβ aggregation. The complete inability of TMS to affect Aβ aggregation
further confirms this hypothesis. Moreover, the methoxy substitution at R5 leads to a more
pronounced effect than that of methoxy substitution at R6. Comparing results of this
chapter for trans-PIC and IRPT to those for resveratrol, which lacks R5 functionalization
and fails to alter LOC-binding (Figure 3.3), provides additional evidence for the
importance of the R5 group on ring B. However, both R5 and R6 hydroxyl groups, forming
a catechol moiety, are needed to observe a potent effect, as with trans-PIC and cis-PIC.
These results were also paralleled by TEM images of Aβ aggregates formed in the presence
of compounds (Figure 4.3). The most effective compounds, trans-PIC and cis-PIC, were
the only compounds to induce a conformational change for Aβ aggregates.
Consistent with our results, a previous study also concluded that the catechol
moiety is essential for the inhibition of Aβ aggregation by showing that entacapone,
tolcapone and five other related catechol containing compounds could effectively inhibit
Aβ fibril formation from monomers [78]. However, this study only evaluated compounds
containing catechol moiety and lacked the comparisons between similar structured noncatechol and catechol molecules. Another study compared inhibitory effects on Aβ
aggregation of quercetin and kaempferol, a catechol containing compound and a non-
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catechol containing compound by removing one of the quercetin’s hydroxyl groups, and
found that to inhibit Aβ aggregation to the same extent, quercetin is required in 1/7 of the
concentration as compared to kaempferol [79].
This study further showed that catechol moiety is important for intervening with
Ab aggregation intermediates’ subsequent growth via association and elongation (Figure
4.5 and Figure 4.6). IRPT and RPT, which substitute a hydroxyl group with a methoxy
group on one position of the catechol, failed to reduce association and elongation. In fact,
IRPT increased Ab aggregate association, which implies that the R5 position might be
more important than R6 position. trans-PIC and cis-PIC, which contain the catechol
moiety, are the only compounds that slowed both processes. It is, however, worth noting
that these two isomers had distinct effects on association and elongation. trans-PIC is more
effective in inhibiting association, while cis-PIC induced a higher reduction in elongation.
It is possible that the geometric difference between trans- and cis-PIC is associated with a
difference in preferred binding sites on Ab aggregates. The proposed molecular
organization of aggregates [45] suggests that association involves R-groups of residues 1224 of the peptide, while elongation involves backbone hydrogen bonds formed during
monomer addition to the ends of existing aggregates. As a result, unique binding
interactions are required to affect the two growth mechanisms distinctly.
However, the catechol structure on ring B is not sufficient for the compound to
affect early stages of aggregation (Figure 4.4). trans-PIC failed to alter oligomer quantities
in both size ranges, although, its geometric rearranged isomer, cis-PIC, exhibited a potent
effect toward reducing larger oligomers which supports the possibility that the geometric
difference could result in altered binding on oligomers. This oligomerization result
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indicating that the presence of a catechol moiety did not increase modulation of
oligomerization is consistent with another study [80]. In this study, oligomerization of Aβ
peptide was evaluated in the presence of catechol containing compounds, luteolin and
quercetin, and their corresponding non-catechol containing compounds, apigenin and
kaempferol, by removing one of the hydroxyl groups. Both non-catechol containing
compounds reduced the quantities of oligomers to a higher extent than their corresponding
catechol containing compounds, demonstrating the catechol structure does not exert
superior effects on altering oligomerization size distribution. Chapter 4 further showed that
IRPT and RPT failed to change oligomerization, while TMS reduced larger size oligomer
quantities.
Together, the results from oligomerization, association and elongation imply that
binding mechanisms between compounds and different Ab aggregate species could be
different. As a result, compounds can affect individual aggregation steps in different
manners. cis-PIC is the only compound effective at altering both early and late stages of
aggregation.
In summary, this study was motivated by our prior results in which we identified
trans-PIC’s superior effect on Ab aggregation over resveratrol, oxyresveratrol and piceid.
To explore other trans-PIC analogs that are effective in modulating Ab aggregation,
methoxy derivatives, IRPT, RPT and TMS, were investigated, as well as its isomer cisPIC. trans-PIC and cis-PIC excel at interfering with LOC binding of aggregates formed
from Ab monomer as well as Ab soluble aggregate association and elongation. The less
pronounced effects of IRPT, RPT and TMS suggest the potent action of trans-PIC and cisPIC may be attributed to the presence of catechol structure on ring B. The early stage of
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aggregation, oligomerization, is affected by compounds in a different mechanism, since
trans-PIC failed to alter oligomers’ size distribution while cis-PIC and TMS reduced the
quantity of large oligomers. Overall, cis-PIC exhibits an enhanced effect over trans-PIC
with the ability to interfere with multiple mechanistic steps of aggregation.
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(3,3’,4,5’-Tetramethoxystilbene, TMS)

Figure 4.1 Structure of piceatannol and derivatives.
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Figure 4.2 Effect of piceatannol and derivatives on Aβ40 monomer aggregation. 20 µM
SEC-purified Aβ40 monomer was aggregated alone (CONT, ) or in the presence of 200
µM trans-PIC ( ), cis-PIC (
), IRPT (
), RPT (
), or TMS ( ). (A) Extent of
aggregation was evaluated by dot blot using LOC antibody detection. (B) LOC intensity
for each dot was quantified and normalized to the intensity of control’s plateau. Results are
representative of four independent experiments. (C) Plateau reduction capability was
evaluated as relative plateau, or the plateau observed in the presence of compound
normalized to the control plateau. Error bars represent SEM, n=3-4. ***p<0.001, *p<0.05,
versus control.
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Figure 4.3 Effect of piceatannol and derivatives on Aβ40 aggregate structure. Aβ40
aggregates were formed from 20 µM monomer in the absence (CONT) or presence of 200
µM piceatannol and derivatives. Samples were grided when the control reaction reached
the equilibrium plateau. Images are representative of three independent experiments. Scale
bar represents 200 nm.
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Figure 4.4 Effect of piceatannol and derivatives on Aβ42 oligomer size distribution. 15
µM Aβ42 monomer was subjected to oligomerization conditions alone (CONT) or with 150
µM piceatannol and derivatives. (A) Oligomerization products were resolved by SDSPAGE and Western blot, and probed using 6E10 antibody. (B) Adjusted volume intensity
of aggregate species of 25-100 kDa (closed bars) and 100-250 kDa (open bars) is reported
relative to control (CONT). Error bars represent SEM, n=3. *p<0.05, versus control.
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Figure 4.5 Effect of piceatannol and derivatives on Aβ40 soluble aggregate association.
2 µM SEC-purified Aβ40 soluble aggregates were incubated alone (CONT, ) or in the
presence of 50 µM trans-PIC ( ), cis-PIC ( ), IRPT ( ), or RPT ( ). Association was
initiated by the addition of 150 mM NaCl. Incubation of soluble Aβ40 soluble aggregates
in the absence of NaCl served as a negative control (
). (A) Samples were monitored
over time by DLS for RH. (B) The rate of association was determined by linear regression.
Results are expressed as the relative association rate, or the association rate observed in the
presence of compounds normalized to the association rate of the control (indicated by the
dashed line at 1). Error bars represent SEM, n=3. ***p<0.001, **p<0.01, *p<0.05, versus
control.
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Figure 4.6 Effect of piceatannol and derivatives on Aβ40 soluble aggregate elongation.
Elongation of immobilized 2 µM SEC-purified Aβ40 soluble aggregate by monomer
addition into the QCM flow cell. (A) Crystal surfaces on which Aβ40 soluble aggregate was
immobilized were exposed to buffer (CONT, ), or 300 µM trans-PIC ( ), cis-PIC ( ),
IRPT ( ), RPT ( ), or TMS ( ). Elongation was initiated via subsequent introduction
of 30 µM monomer. Samples were monitored by QCM for mass change on the crystal. (B)
The rate of elongation was determined by linear regression. Results are expressed as
relative elongation rate, or the elongation rate following compound exposure normalized
to the elongation rate of control (indicated by the dashed line at 1). Error bars represent
SEM, n=3-4. ***p<0.001, *p<0.05, versus control.
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CHAPTER 5
EFFECT OF PICEATANNOL ON BINDING INTERACTIONS BETWEEN
AMYLOID-β AGGREGATES AND SUPPORTED PHOSPHOLIPID BILAYER
MODEL MEMBRANE CONTAINING POPC AND DPPC
5.1 Introduction
As a key component in the pathogenesis of AD, the neurotoxicity mechanism of
Aβ aggregates has been extensively studied. It is well recognized that the initial interactions
of aggregated Aβ with the cell membrane play an important role in the disease propagation.
Aβ aggregates can bind lipids, perturb membranes, alter membrane fluidity and disrupt cell
functions [81]. In vivo study has shown that Aβ deposition on the cell surface plasma
membrane was an initial event in formation of aggregates that gradually develop into
plaques [82]. In vitro studies, using model membranes and biological membranes, have
shown that electrostatic binding of Aβ peptides to phospholipid polar head groups could
contribute to Aβ neurotoxicity [83,84] and that soluble Aβ aggregates are able to partition
into the hydrophobic core of membranes [85]. Despite extensive research, the exact
mechanism of interactions between Ab aggregates and cell membranes is still under debate,
possibly because interactions are highly dependent on the physico-chemical state of both
Ab aggregates and membranes. Ab aggregates’ aggregation extent, size, surface
hydrophobicity and conformation [81,86], as well as, membrane composition, charge,
hydrophobicity and phase [87] are all postulated to be important influential factors.
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This chapter is focused on better understanding the binding interactions between
soluble Ab aggregates and supported phospholipid bilayers (SPBs) which are commonly
used to mimic the cell membrane for studies of lipid-protein interactions and membranebased biosensors [88]. The state of Ab aggregates was varied based on our previous work
in which piceatannol (PIC) showed a potent effect on modulating Ab aggregation by
inducing a conformational change. Thus, introducing PIC in the aggregation process can
produce Ab aggregates with a modified conformation. A comparison of binding rates
between SPBs and Ab aggregates with or without PIC modification confirmed that Ab
aggregate conformation plays an important role in the binding interaction. In addition, the
state

of

SPBs,

which

were

composed

of

1-palmitoyl-2-oleoyl-sn-glycero-3-

phosphocholine (POPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), was
also varied by changing compositions of POPC and DPPC. POPC contains a
phosphocholine headgroup with one saturated acyl chain of 16 carbon atoms and one acyl
chain of 18 carbon atoms having a double bond, and DPPC contains a phosphocholine
headgroup with two saturated acyl chains of 16 carbon atoms (Figure 5.1). Due to the
difference of one double bond in tails, DPPC has a higher melting temperature and a lower
fluidity than POPC. Thus, SPBs formed with increased DPPC mixtures exhibit decreased
membrane fluidities. A comparison of binding rates between various SPBs and Ab
aggregates confirmed that membrane fluidity can affect lipid-protein interactions.
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5.2 Materials and Methods
5.2.1 Preparation of Aβ40 Soluble Aggregate
The unmodified Aβ40 soluble aggregate (control) was prepared and purified as
described in Section 2.11. PIC modified Aβ40 soluble aggregate was prepared in the same
manner except the aggregation occurred in the presence of 120 µM PIC.
5.2.2 Characterization of Aβ40 Soluble Aggregate by Dot Blot
4 µL of 2 µM control Aβ40 soluble aggregate, 2 µM PIC-modified Aβ40 soluble
aggregate and 80 µM Aβ40 monomer were dotted on nitrocellulose membrane and probed
with conformational specific antibody LOC, as described in Section 2.3.1. Monomer
sample serves as a negative control.
5.2.3 Characterization of Aβ40 Soluble Aggregate by ANS
ANS dissolved in 50 mM DMSO was mixed with control Aβ40 soluble aggregate
or PIC-modified Aβ40 soluble aggregate and diluted in 40 mM Tris-HCl to yield a final
concentration of 2 µM Aβ40 soluble aggregate and 50 µM ANS. The ANS emission
spectrum was recorded with excitation at 350 nm and emission from 400 to 600 nm.
5.2.4 Formation of SPBs
POPC (Avanti Polar Lipids, Alabaster, AL) was stored (-20 °C) as a chloroform
solution, and DPPC (Avanti Polar Lipids, Alabaster, AL) was stored (-20 °C) as a
lyophilized powder and reconstituted in chloroform upon use. To create lipid bilayer with
various fluidities, chloroform solution was used as a solvent to dissolve molecular
combinations of POPC and DPPC at 100:0, 90:10, 80:20 and 70:30. SPBs were formed
using a procedure similar to that previously described [89]. Briefly, chloroform was
removed by evaporation in an R-200 rotary evaporator (Buchi, Flawil, Switzerland) to
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yield a thin film, which was dried under vacuum for 12-24 h. To initiate liposome
formation, the resulting thin film was hydrated in 40 mM Tris-HCl containing 50 mM NaCl
to yield multilamellar vesicles. These vesicles were further agitated by 5 cycles of freezing
and thawing to yield large multilamellar vesicles (LMVs). LMVs were filtered through
extrusion using a LiposoFast extruder (Avestin, Ottawa, Canada) filtered with a 50 nm
polycarbonate filter a total of 11 times to yield a suspension of small unilamellar vesicles
(SUVs). SUVs formed in this manner displayed an RH of approximately 65 nm, as observed
using DLS. SUVs were stored at 4 °C for up to 7 days. Upon use, SUVs were diluted in 40
mM Tris-HCl with the addition of 1 M NaCl and 500 mM CaCl2 for a final solution
containing 50 mM NaCl and 2.5 mM CaCl2. SUVs were injected into the QCM flow cell
at 40 °C in which they rapidly adhered onto the SiO2 covered crystal surface to the critical
coverage and subsequently ruptured to form SPBs (Figure 5.2).
5.2.5 Binding of Aβ40 Soluble Aggregate on SPBs
Following formation of the SPB on the surface of a SiO2–coated crystal, 2 µM Aβ40
soluble aggregate (control or PIC-modified) was introduced into the flow cell at a flowrate
of 0.02 mL/min. Soluble aggregate binding to the SPBs was evidenced as an increase in
crystal mass. Results were plotted as changes in mass versus time. The binding rate was
defined as the slope of the linear regression of this plot.
5.3 Results
5.3.1 Characteristics of Aβ Soluble Aggregate
To confirm the effect of PIC on conformation of Aβ soluble aggregates, LOC
binding and ANS fluorescence were used to probe aggregate structure. Compared with
control Aβ soluble aggregates, PIC-modified Aβ soluble aggregates exhibit reduced LOC
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binding (Figure 5.3A). As LOC intensity reflects the quantity of a specific LOC
recognizable conformation, which is common in fibrillar structures, the difference between
LOC intensity of control Aβ aggregates and PIC-modified Aβ aggregates represents a
difference in aggregates’ conformation. In addition, PIC-modified Aβ aggregates showed
a decrease in ANS fluorescence (Figure 5.3B), indicating a reduced surface hydrophobicity
of PIC-modified Aβ aggregates and providing more support for conformational difference.
5.3.2 Both the State of Aβ Soluble Aggregate and SPBs Affect Binding Interactions
QCM was used as a surface-specific measurement technique to examine Aβ soluble
aggregates-lipid interactions. The binding of 2 µM control Aβ soluble aggregates (Figure
5.4A) and 2 µM PIC-modified Aβ soluble aggregates (Figure 5.4B) on SPBs, with various
POPC/DPPC compositions, was evaluated by a change in deposited mass. Aβ soluble
aggregates formed in the presence of PIC exhibited a negligible binding rate, regardless of
the lipid bilayer composition, compared with that of control (Figure 5.4C). This result
demonstrates that the conformation of Aβ soluble aggregate can substantially affect ability
of Aβ aggregates to bind zwitterionic lipids.
Similarly, varying SPBs fluidity, by modifying the POPC and DPPC composition,
also had an effect on the binding interaction of control Aβ aggregates. As the molecular
composition of DPPC increases from 0 % to 20 %, lowering the lipid fluidity, the binding
rate of control Aβ soluble aggregates decreases. Moreover, further increasing DPPC
composition to 30 % had an opposite effect and induced a sudden increase in binding rate.
However, this trend was not observed for PIC-induced Aβ soluble aggregate. The result
for binding interactions between control Aβ soluble aggregate and SPBs with various
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compositions demonstrates that membrane state, fluidity in particular, is an important
factor for binding of Aβ soluble aggregates.
5.4 Discussion
Aβ peptide and Aβ aggregates have been extensively studied for their interactions
with lipid membranes. Aβ aggregates were proposed to trigger age-related
neurodegenerative disease by induction of unregulated membrane permeabilization [90].
AFM images showed donut-shaped Aβ aggregates decorate lipid bilayer surfaces,
suggesting pores perforating the underlying membranes which form ion channels [18]. Aβ
aggregates interacting with lipid membranes also have been shown to affect membrane
fluidities. The effects on membrane fluidity might contribute to the dysfunction of cells,
such as, calcium signaling, activity of various enzymes and lipid transport [91-93].
However, the direction of the fluidity change has not been consistently observed. This
inconsistency may result from differences in membrane source and preparation, Aβ
aggregation state and the properties of fluorescence probes used for measuring fluidity
[81]. These Aβ-lipid interactions initiate with the binding interaction between Aβ and
lipids. Thus, it is vital to better understand this binding interaction. It has been shown that
Aβ peptide and aggregate are capable of binding to phospholipid membranes with a
relatively high affinity [89,94,95], and the conformational changes of Aβ aggregates play
a prominent role in the protein-membrane interaction [96,97]. Moreover, differences in
binding affinity between Aβ aggregates and lipid membranes have been observed to be
related to aggregate toxicity [98]. A study, using rat cerebellar granule cells, has shown
that Aβ aggregated species that exhibited propensity to bind to the phospholipid vesicles
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were the toxic species that induced necrosis whereas the Aβ aggregate species that did not
bind to vesicles, in contrast, did not cause detectable neuronal death [99].
In this study, we built a lipid bilayer membrane by forming SPBs on a SiO2-coated
crystal whose deposited mass was continuously monitored. After the introduction of Aβ
soluble aggregates over SPBs, the protein-lipid binding could be identified by an increase
in the crystal mass, and the propensity for binding could be quantified by the rate of mass
increase. Aβ soluble aggregates were observed to bind SPBs containing POPC and DPPC
at all four compositions (POPC/DPPC, 100/0, 90/10, 80/20, and 70/30) (Figure 5.4A).
Moreover, different membrane compositions exhibited different binding propensities
toward control Aβ soluble aggregates. SPBs formed with 80 % POPC and 20 % DPPC
were the least favored for binding interaction. As the molecular composition of DPPC
decreases from 20 % to 10 % and eventually to 0 %, the binding interaction became more
favorable (Figure 5.4C). One possible explanation for this trend is that membrane fluidity
influenced the binding interaction. As DPPC concentration decreased from 20 % to 0 %,
the membrane fluidity would increase, and this change results in more favored binding.
The hypothesis that binding between Ab peptides and lipid membranes is influenced by
the membrane fluidity has been proposed based on the observation that increasing
cholesterol concentration in the lipid mixture could increase the binding and cholesterol is
known to alter membrane fluidity [98]. However, the effect of cholesterol on membrane
fluidity is not agreed upon and the inconsistent results might be attributed to the differences
in membrane composition, phase and temperature [97,99]. Another study demonstrated
that increasing membrane fluidity would increase the binding strength between lipid
bilayer and a mammalian protein, 5-lipoxygenase, using fluoresce spectroscopy

74

measurements [100]. In our investigation, when the DPPC concentration was further raised
to 30 %, a strong binding interaction was recovered. It is possible that as the quantity of
DPPC continued to increase to 30 %, the binary lipid bilayer system had a tendency to
separate the gel like DPPC from the liquid like POPC and cause the formation of phasesegregated domains. The presence of these domains could attract Aβ aggregates to cluster
either with high fluidity areas or at phase boundaries, manifesting in a higher quantity of
bound Aβ aggregates than lipids bilayers without such domains. Lipid rafts are a common
form of lipid bilayer phase separation and the integrity of lipid rafts has been reported to
be important for the binding of Aβ aggregates to the cell surfaces [101].
In contrast, the binding interactions between PIC-modified Aβ soluble aggregates
and SPBs were minimal (Figure 5.4B and C) for all four lipids compositions. This
difference in binding propensity could be explained by the conformational difference
between two types of Aβ soluble aggregates, as PIC-modified Aβ soluble aggregates have
less hydrophobic surfaces and much weaker LOC antibody recognition than control Aβ
soluble aggregates (Figure 5.3). Aβ aggregates’ conformation might be important for
protein-lipid interaction as it has been shown that a conformational change of Aβ oligomers
could cause a change in Aβ induced ion conductance across membranes, representing a
change in membrane permeability [96].
This work is part of a collaboration with Dr. Mark Uline at University of South
Carolina and Dr. Amir Farnoud at Ohio Unviersity to further investigate lipid membrane
and Aβ aggregate interactions. Dr. Uline’s group is focused on understanding the complex
interactions between Aβ aggregates and lipids by molecular modeling of lipid bilayers with
various POPC/DPPC compositions and their binding with Aβ aggregates. Dr. Farnoud’s
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group will confirm the fluidity differences between four types of lipid bilayers using
fluorescence anisotropy with fluorophores DPH and TMA-DPH to confirm fluidity
differences, as well as evaluate the disruption of phospholipid monolayers induced by Aβ
aggregates using Langmuir-Blodgett trough and study the effects of Aβ aggregates on lipid
bilayer membrane permeabilization using carboxyfluorescein fluorescence. The
conformational change of Aβ aggregates induced by the presence of PIC might alter Aβ
aggregates’ effect on membrane disruption and permeability, and this hypothesis will also
be evaluated.
Together, our work experimentally determined the binding interactions between Aβ
aggregates and SPBs and demonstrated that Aβ aggregates’ conformational change
induced by PIC could reduce the binding propensity. Furthermore, our collaborators will
experimentally evaluate Aβ aggregates’ effect on membrane disruption and permeability
[102], and the experimental data will be explained by the development of a molecular
mechanism through computational modeling.
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POPC

DPPC

Figure 5.1 Structures of POPC and DPPC. POPC and DPPC contain identical
phosphocholine headgroups and differ by one of the two acyl chains. POPC contains a
single double bond, while DPPC is fully saturated.
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Figure 5.2 SPBs formation on a SiO2 covered crystal monitored by QCM. The
attachment of SUVs on the crystal surface was evidenced by the decrease in measured
harmonic frequency ( , Δ f ) and increase in measured energy dissipation (
, Δ D ).
Vesicles rupture and SPBs formation were evidenced by a subsequent increase in
frequency and decrease in dissipation.
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Figure 5.3 Control Aβ40 aggregate and PIC-modified Aβ40 aggregate have distinct
conformations. (A) 2 µM SEC-purified Ab40 soluble aggregates formed in the absence
(CONT) or presence of PIC (PIC), or 80 µM SEC-purified Ab40 monomer (MON) were
probed with conformational specific antibody, LOC. (B) ANS spectrum for 2 µM control
Ab40 soluble aggregates (left) and 2 µM PIC-modified Ab40 soluble aggregates (right) both
purified by SEC. Fluorescence emission was measured from 400 to 600 nm with excitation
at 350 nm. Dashed line indicates sample reading, and solid line indicates blank reading (40
mM Tris-HCl). ANS fluorescence value is the AUC from 450 to 550 nm, corrected by
blank subtraction, shown as the shaded area.
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Figure 5.4 Effect of piceatannol on Aβ aggregate binding onto SPBs with various
compositions. Unmodified Aβ aggregate (A) and PIC-modified Aβ aggregate (B) were
introduced into the QCM flow cell in which SPBs with various compositions were formed
on the surface of a SiO2 covered crystal, specifically, POPC:DPPC of 100:0 (
), 90:10
(
), 80:20 (
) and 70:30 (
). Binding of aggregates to the SPB was monitored via
QCM as an increase in mass with time, and (C) The binding rate was determined by linear
regression. A comparison between binding rate for unmodified Aβ aggregate (open bars)
and PIC-modified Aβ aggregate (closed bars) revealed significant reductions for all lipid
mixtures. Error bars represent SEM, n=3. *p<0.05, ***p<0.001, versus control.
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CHAPTER 6
CONCLUSION
Protein aggregation and amyloid formation has attracted research attention from a
wide range of scientific disciplines, ranging from physics and chemistry to biology and
medicine, and this great interest comes from the recognition that protein aggregation is
associated with approximately 50 human diseases, such as AD, Parkinson’s disease,
Huntington’s disease and Type II diabetes [13]. Among these diseases, AD poses the most
serious threat to human health and society because of its high prevalence, incidence,
mortality, morbidity and cost of caregiving. Currently, all treatments for AD can only
temporarily alleviate the symptoms without affecting the underlying cause of the disease,
Aβ peptide aggregation. Stilbenes, as a sub-class of polyphenols, have shown profound
bioactivities including anti-inflammatory, anti-oxidant, anti-diabetic, anti-cancer and
cardioprotective properties. Based on the observation that they can interact with peptides
and proteins [22], stilbenes possess potential to intervene with Aβ aggregation and thus
present therapeutic roles for AD.
In Chapter 3, resveratrol and derivatives (RES, PIC, OXR and PID) were examined
for their capabilities to modulate Aβ aggregation. All compounds were able to alter the
morphologies of Aβ aggregates and these conformational modifications are a result of their
intervening with multiple mechanistic steps of Aβ aggregation. While no compounds were
capable of changing oligomer sizes, RES and PIC were able to reduce oligomer surface
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hydrophobicity. When Aβ soluble aggregates were formed and stimulated to grow through
association and elongation in the presence of compounds, they showed distinct effects. PIC
is the only compound that can inhibit both mechanisms. OXR and PID have inhibitory
capability on elongation. In contrast, RES and PID promoted the rate of elongation and
association, respectively. This work demonstrates that PIC has superior effects on
modulating Aβ aggregation and it exerts such effects by inducing a conformational change
in Aβ aggregates.
Chapter 4 further explored modulating effects on Aβ aggregation of trans-PIC, its
derivatives (IRPT, RPT, TMS) and its isomer cis-PIC. Both trans-PIC and cis-PIC could
significantly affect Aβ aggregation, reduce association and elongation, and change the
morphologies of Aβ aggregates. However, only cis-PIC was able to alter the oligomer size
distribution. Substituting hydroxyl groups on trans-PIC with methoxy groups substantially
impaired compounds capability to intervene with Aβ aggregation. IRPT and RPT,
replacing one of the catechol hydroxyl groups with a methoxy group, showed inhibitory
effects on Aβ aggregation, but to a much lesser extent. TMS, replacing all hydroxyl groups
with methoxy groups, had no effect on aggregation. Moreover, IRPT, RPT and TMS all
failed to reduce association and elongation. This work demonstrates the importance of
catechol moiety for the compounds to be able to intervene with overall Aβ aggregation and
later stage aggregation. However, the catechol is not sufficient for the compounds to be
able to intervene with the early oligomerization process.
Chapter 5 is part of a collaboration with other groups to study the interactions
between Ab aggregates and lipid membranes. This part of the study is focused on
understanding the protein-lipid binding propensity by changing the state of either protein
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or membrane. Lipid bilayers with different fluidities tend to bind Ab aggregates with
different rates. As lipid bilayers become less fluid, through increasing DPPC percentage in
a POPC/DPPC binary mixture, the binding rate decreases. However, further increasing
DPPC composition showed a recovered binding propensity, which might be a result of
local phase separation. PIC-modified Ab aggregates showed very limited binding
propensity with all types of lipid bilayers investigated here which could be explained by
an Ab aggregates’ conformational change induced by PIC.
To sum up, this study evaluated the effects of eight stilbenes’ on intervening with
Ab aggregation, identified trans-piceatannol and cis-piceatannol having the most potent
effects, and proposed this superior intervention might be a result of the presence of catechol
moiety in their structures. Moreover, the conformational change of Ab aggregates induced
by trans-piceatannol caused a reduction of binding interaction between aggregates and
supported lipid bilayer. Thus, trans-piceatannol and cis-piceatannol showed potential
therapeutic values for AD.
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CHAPTER 7
FUTURE WORK
In the near future, this study can be continued from two aspects. First, it will be
important to confirm that Ab aggregates conformational change induced by piceatannol
can alter the cytotoxicity of Ab aggregates. To examine this possibility, a caspase-3/7 assay
will be employed to assess the toxicity of Ab aggregates formed in the presence or absence
of piceatannol. Caspase-3/7 assay measures caspase-3/7 activities, which are indicative of
the level of cell apoptosis. In addition, a satisfactory explanation for the binding propensity
differences between control Ab aggregates and four types of lipid bilayers observed in
Chapter 5 is needed. Specifically, we will examine the hypothesis of a phase transition
occurring for lipid bilayers with 70 % POPC and 30 % DPPC at 40 °C. Here, binding
experiments will be performed at a lower temperature, where lipid bilayers with higher
fluidities (POPC/DPPC, 90/10 and 80/20) are expected to undergo a similar phase
transition and thus exhibit a higher binding propensity.
The desire to discover biological agents that can inhibit or interfere with Aβ
aggregation, the pathological process of AD, has driven extensive research in evaluating
such effects of both natural and synthetic compounds, for over two decades. The numerous
inhibitors that have been examined to date range from small molecules, peptides and
peptideomimetics to nanoparticles. These past endeavors have accumulated a great amount
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of valuable experimental data relating compounds to their capabilities of binding,
interfering and inhibiting diverse Aβ aggregated species. However, each individual study
could only assess a few compounds and deduce structure-activity relationships
accordingly, since performing such investigations requires intensive laboratory work, high
cost for materials and equipment, as well as, a long experimental time frame. Efforts have
been made to manually summarize results from different studies in order to find common
chemical structures that are important for inhibiting aggregation [103,104] and aid the
design of effective inhibitors, but the result is far from satisfactory. It is probably because
the number of parameters to describe the properties of compounds and Aβ aggregates is
too large for humans to recognize underlying patterns and understand the causative
mechanisms directly. Based on the fact that we have access to a large number of valuable
experimental data for both positive inhibitors and negative inhibitors, in the future, it is
feasible to develop a machine learning pipeline that, given a new compound, outputs its
predicted possibility of being a positive inhibitor and the predicted effectiveness. The
design of this pipeline would include data collection and clean, feature extraction and
transformation, classification model training, model performance evaluation and finally
prediction. This pipeline would help researchers to quickly screen a large number of novel
compounds and narrow the scope of experimental evaluation to the compounds that are
most likely to be positive inhibitors. As a result, it will increase the successful rates for
identifying effective inhibitors and save a great amount of time and money.
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